Explore every episode of the podcast STAT Stitch Deep Dive Podcast Beyond The Bedside

According to your sources, Diffuse Axonal Injury (DAI) is widespread axonal damage caused by the physical forces of a mild, moderate, or severe traumatic brain injury (TBI)[1].

Physical Mechanism

• Traumatic Impact Forces: DAI occurs due to the tensile forces of trauma sustained during a head injury[1].
• Cellular Progression: Rather than immediate shearing or tearing of the axon at the moment of impact, the trauma alters axonal functioning[1]. This leads to progressive axonal swelling and disconnection over a 12- to 24-hour period (or longer)[1].

Common Causes of Head Injuries & TBIs

Because DAI is a generalized form of TBI resulting from traumatic impact, it stems from the common causes of head trauma[1][2]:

• Motor vehicle accidents (most common)[2]
• Falls (most common)[2]
• Sports-related trauma[2]
• Assaults[2]
• Firearms[2]
• Recreational injuries[2]
• War-related injuries

Core Intracranial Dynamics (The 20%)

• Volume Distribution: The enclosed skull holds 78% brain tissue, 12% blood, and 10% CSF[1][2].
• Monro-Kellie Doctrine: Intracranial volume is constant; an increase in any component requires compensatory displacement of others to maintain constant volume within the skull[2].
• Key Clinical Target Values: Normal ICP is 5–15 mm Hg (sustained >20 mm Hg is abnormal)[2]. Normal CPP is 60–100 mm Hg (CPP = MAP − ICP)[3]. A CPP <50 mm Hg causes cerebral ischemia, while <30 mm Hg is incompatible with life[3]. Cerebral autoregulation maintains constant blood flow between a MAP of 70–150 mm Hg[2].
• PaCO2 Impact: Elevated PaCO2 causes potent cerebral vasodilation, increasing blood volume and ICP[4].

2. Essential Recognition & Red Flags

• LOC: Change in level of consciousness is the most sensitive and reliable indicator of neurological decline[5].
• Cushing's Triad: Systolic hypertension with widening pulse pressure, bradycardia, and irregular respirations signify brainstem compression and impending herniation[5].
• Pupils & Motor Response: A fixed, unilateral dilated pupil indicates ipsilateral CN III compression[6]. Decerebrate posturing (extensor) reflects midbrain/brainstem damage and is more severe than decorticate (flexor) posturing[6].
• Compliance Loss: A ventriculostomy waveform where P2 is higher than P1 indicates compromised compliance[7][8].

3. High-Yield Condition Comparisons

• Epidural Hematoma (EDH): Arterial tear (middle meningeal artery) causing rapid compression; presents with unconsciousness → lucid interval → rapid decline[9]. Requires emergency surgical evacuation[9].
• Subdural Hematoma (SDH): Venous tear (bridging veins) progressing slower; chronic forms are common in older adults due to brain atrophy[9][10].
• Basilar Skull Fracture: Marked by Battle's sign, raccoon eyes, and CSF otorrhea/rhinorrhea (verified via halo sign or positive glucose)[11][12].
• Bacterial Meningitis: Presents with fever, severe headache, and nuchal rigidity[13]. Diagnostic LP reveals decreased CSF glucose, elevated protein, and high neutrophils[13][14].

4. Priority Clinical Actions

• Airway & Position: Secure airway (GCS ≤8 requires intubation)[15]. Maintain HOB elevated 30 degrees with head midline to optimize venous drainage and CPP[16]. Avoid extreme neck or hip flexion[16].
• Medical Interventions: Administer Mannitol or Hypertonic Saline to draw edema from tissue into circulation[17]. Give prompt IV antibiotics right after cultures for meningitis[14].
• Critical Contraindications: Lumbar puncture is contraindicated with elevated ICP due to herniation risk[18]. Avoid NG tubes and nasotracheal suctioning in basilar fractures/CSF leaks[15][19]. Enforce respiratory isolation for meningococcal meningitis[20].

An Epidural Hematoma (EDH) and a Subdural Hematoma (SDH) are two distinct forms of focal intracranial bleeding caused by head trauma[1][2]. They differ significantly in anatomical location, primary bleeding source, clinical progression, and at-risk populations[2][3].

1. Side-by-Side Comparison

FeatureEpidural Hematoma (EDH)Subdural Hematoma (SDH)Anatomical LocationBetween the dura mater and the inner surface of the skull[2][4].Between the dura mater and the arachnoid layer of the meninges[2][4].Primary Vessel InvolvedUsually arterial (most commonly a tear of the middle meningeal artery beneath the temporal bone)[2][5]. Can occasionally be venous from a dural venous sinus tear[2].Usually venous (tear of bridging veins draining from the brain surface into the sagittal sinus)[2]. Can occasionally be arterial[2].Rate of Bleeding & OnsetRapidly developing due to high-pressure arterial expansion; considered a critical neurologic emergency[2].Usually slower to develop due to lower-pressure venous bleeding[2]. Divided into acute, subacute, and chronic forms[2][3].Classic Clinical PresentationUnconsciousness at the scene → brief lucid interval → rapid neurologic deterioration and decreased level of consciousness (LOC)[2].Symptoms of progressive increased intracranial pressure (ICP) and brain compression: headache, drowsiness, confusion, decreasing LOC, and ipsilateral fixed/dilated pupil[2].Associated Etiology & Risk FactorsFrequently associated with linear skull fractures crossing major dural arteries (e.g., temporal bone fractures)[2][5].Older adults (due to brain atrophy stretching bridging veins), alcohol use (risk of falls), and anticoagulant therapy[2][3].Surgical TreatmentRapid surgical evacuation via craniotomy or burr-hole decompression to prevent brain herniation[2][6].Surgical evacuation, decompression, or membranectomy (craniotomy or burr holes) depending on size and impairment[2].

2. Key Clinical Nuances

• The EDH Lucid Interval: The hallmark of an arterial EDH is a patient who temporarily regains clarity after an initial knockout, only to rapidly deteriorate as arterial blood expands inside the closed skull[2]. Emergency surgical intervention is required before herniation occurs[2][6].
• Subdural Subtypes (Acute, Subacute, Chronic):
  • Acute SDH: Manifests within 24–48 hours of severe trauma with immediate deterioration[2].
  • Subacute SDH: Appears within 48 hours to 2 weeks post-injury; blood breakdown products draw fluid into the subdural space, causing late expansion[2][3].
  • Chronic SDH: Develops over weeks or months (often >20 days) after a seemingly minor or forgotten head injury[2][3].
• Diagnostic Pitfalls in Older Adults: Chronic SDH in older adults is frequently misdiagnosed as dementia, a transient ischemic attack (TIA), or a stroke because symptoms present as subtle confusion, memory loss, and lethargy rather than acute ICP spikes[3].

Core Intracranial Dynamics (The 20%)

• Volume Distribution: The enclosed skull holds 78% brain tissue, 12% blood, and 10% CSF[1][2].
• Monro-Kellie Doctrine: Intracranial volume is constant; an increase in any component requires compensatory displacement of others to maintain constant volume within the skull[2].
• Key Clinical Target Values: Normal ICP is 5–15 mm Hg (sustained >20 mm Hg is abnormal)[2]. Normal CPP is 60–100 mm Hg (CPP = MAP − ICP)[3]. A CPP <50 mm Hg causes cerebral ischemia, while <30 mm Hg is incompatible with life[3]. Cerebral autoregulation maintains constant blood flow between a MAP of 70–150 mm Hg[2].
• PaCO2 Impact: Elevated PaCO2 causes potent cerebral vasodilation, increasing blood volume and ICP[4].

2. Essential Recognition & Red Flags

• LOC: Change in level of consciousness is the most sensitive and reliable indicator of neurological decline[5].
• Cushing's Triad: Systolic hypertension with widening pulse pressure, bradycardia, and irregular respirations signify brainstem compression and impending herniation[5].
• Pupils & Motor Response: A fixed, unilateral dilated pupil indicates ipsilateral CN III compression[6]. Decerebrate posturing (extensor) reflects midbrain/brainstem damage and is more severe than decorticate (flexor) posturing[6].
• Compliance Loss: A ventriculostomy waveform where P2 is higher than P1 indicates compromised compliance[7][8].

3. High-Yield Condition Comparisons

• Epidural Hematoma (EDH): Arterial tear (middle meningeal artery) causing rapid compression; presents with unconsciousness → lucid interval → rapid decline[9]. Requires emergency surgical evacuation[9].
• Subdural Hematoma (SDH): Venous tear (bridging veins) progressing slower; chronic forms are common in older adults due to brain atrophy[9][10].
• Basilar Skull Fracture: Marked by Battle's sign, raccoon eyes, and CSF otorrhea/rhinorrhea (verified via halo sign or positive glucose)[11][12].
• Bacterial Meningitis: Presents with fever, severe headache, and nuchal rigidity[13]. Diagnostic LP reveals decreased CSF glucose, elevated protein, and high neutrophils[13][14].

4. Priority Clinical Actions

• Airway & Position: Secure airway (GCS ≤8 requires intubation)[15]. Maintain HOB elevated 30 degrees with head midline to optimize venous drainage and CPP[16]. Avoid extreme neck or hip flexion[16].
• Medical Interventions: Administer Mannitol or Hypertonic Saline to draw edema from tissue into circulation[17]. Give prompt IV antibiotics right after cultures for meningitis[14].
• Critical Contraindications: Lumbar puncture is contraindicated with elevated ICP due to herniation risk[18]. Avoid NG tubes and nasotracheal suctioning in basilar fractures/CSF leaks[15][19]. Enforce respiratory isolation for meningococcal meningitis[20].

this episode goes over the 4 kinds of stokes from a high level overview

the intro episode to the clinical judgement model

Burn Classification & TBSA Assessment Burn severity depends on depth, extent (TBSA), location, and patient risk factors[1]. Depth is classified as partial-thickness (epidermal/dermal; painful, red, blistered) or full-thickness (dermal destruction, painless, leathery eschar, visible thrombosed vessels)[2]. TBSA is estimated using the Rule of Nines for adults or the Lund-Browder chart for children[6]. Referral to a burn center is indicated for partial-thickness burns >10% TBSA, chemical/electrical burns, inhalation injury, or burns of the face, hands, feet, genitalia, perineum, or joints[7]. Face, neck, and circumferential torso burns threaten ventilation[8]. Circumferential limb burns impair perfusion, requiring escharotomy[8][9].

Emergent Phase Pathophysiology & Resuscitation The emergent phase (first 72 hours) prioritizes burn shock and gas exchange[10]. Loss of capillary seal triggers a massive fluid shift from the intravascular to the interstitial space (third spacing), causing severe hypovolemia, hemoconcentration, high blood viscosity, and increased peripheral resistance[10]. Damaged cells release potassium (hyperkalemia), and sodium moves into the interstitium (hyponatremia)[13][14]. Inhalation injuries (carbon monoxide, above/below glottis) cause mucosal edema, obstruction, and pneumonia (the leading cause of death)[9]. Myoglobinuria (from electrical muscle damage) can block renal tubules, causing acute kidney injury (AKI)[18][19]. Priority care includes early intubation, 100% humidified O2, and resuscitation[20][21]. The ABA formula dictates 2–4 mL Lactated Ringer's per kg per % TBSA in the first 24 hours (half in the first 8 hours)[22]. Target clinical parameters are MAP >65 mmHg, HR <120 bpm, and adult urine output of 0.5–1 mL/kg/hr (75–100 mL/hr for electrical burns)[25].

Acute, Rehabilitative & Psychosocial Care The acute phase begins with diuresis and ends when wounds are nearly healed[26]. Sepsis, often from gram-negative bacteria or Candida, is a leading cause of death during this immunosuppressed period[27][28]. Stress-induced hypermetabolism causes protein catabolism and transient hyperglycemia, requiring early enteral nutrition and insulin[29]. Excision and grafting (autograft, CEA, or Integra) are vital for full-thickness wounds[32]. Pain is managed with continuous IV opioids, procedural breakthrough doses, and anxiolytics[36][37]. Continuous physical therapy and splinting prevent contractures[38][39]. In the rehabilitation phase, hypertrophic scars are minimized using custom-fitted pressure garments worn up to 23 hours daily for 12–18 months[40][41]. Hydration and antihistamines help relieve severe itching[40][42]. Older adults face higher mortality due to thinner skin, delayed healing, and co-morbidities[43]. Support groups and psychiatric interventions address emotional needs, body image changes, and PTSD[44].

Primary Headaches[1]

• Tension (TTH): Bilateral, dull bandlike pressure[1][2]. No nausea[2]. Tx: NSAIDs[3][4]. Prev: Amitriptyline[3][5].
• Migraine: Unilateral throbbing, ± aura[1][6]. Triggers: stress, red wine[6][7]. Acute: Triptans (sumatriptan; contraindicated in CAD, ischemic stroke, uncontrolled HTN)[5]. Prev: Topiramate, β-blockers, Botox[3].
• Cluster: Severe unilateral orbital pain in clusters[1][4]. ptosis, tearing[1][4]. Tx: High-flow 100% O2 (7-12 L/min)[3][8], triptans[8]. Prev: Verapamil[8].
• Medication Overuse (MOH): Daily headache from analgesic overuse. Tx: Stop drug[8].

Seizure Disorders[9]

• Def: ≥2 unprovoked seizures >24h apart[9].
• Classes: Generalized (bilateral hemispheres, e.g., tonic-clonic with LOC[10][11]) vs. Focal (1 hemisphere, aware vs. impaired[10][12]).
• Status Epilepticus (SE): Seizure >5 min or recurrent; emergency[12]. Tx: IV Lorazepam, then fosphenytoin[13].
• Nursing Care: Airway, turn on side, do not restrain, never insert objects in mouth, pad rails, record phases[14][15].

Restless Legs Syndrome (RLS)[16]

• Leg paresthesias, worse at rest/night, relieved by movement[16][17]. Basal ganglia dopamine dysfunction[17]. Tx: Dopamine agonists (ropinirole), gabapentin[17].

Degenerative Neurologic Disorders[1]

• Multiple Sclerosis (MS): Autoimmune T-cell CNS demyelination[18][19]. Signs: optic neuritis, spasticity, ataxia, bladder dysfunction[20][21]. Tx: DMDs (interferons)[22], steroids for relapses[22].
• Parkinson's (PD): Substantia nigra DA neuron loss; DA/ACh imbalance[23]. Key: resting tremor ("pill-rolling"), cogwheel rigidity, bradykinesia (masked facies, shuffling gait), postural instability[23]. Tx: Levodopa/Carbidopa (avoid protein meals[26]), DA agonists, DBS[25].
• Myasthenia Gravis (MG): Autoimmune AChR antibody destruction[29]. Fluctuating weakness (ptosis/diplopia; worsens with activity, improves with rest)[29]. Dx: Edrophonium test (atropine bedside)[30].
  • Myasthenic Crisis: Respiratory failure[30]; Tx: IVIG, plasmapheresis[31].
  • Cholinergic Crisis: Excess anticholinestase[30]; SLUDGE signs[30]; Tx: hold drugs, atropine[30].
  • Tx: Pyridostigmine[30].
• Amyotrophic Lateral Sclerosis (ALS): Upper/lower motor neuron degeneration; cognition spared[32][33]. Wasting, bulbar signs. Death: respiratory failure[32]. Tx: Riluzole[32].
• Huntington's (HD): Autosomal dominant CAG repeats[33]. ACh/GABA deficit, excess DA[33]. Key: chorea, psychiatric decline, dementia[33][34]. Caloric needs: 4000-5000 kcal/day[34]. Tx: Tetrabenazine[34].

80/20 Clinical Stroke Summary

Core Concepts & Emergency Recognition A stroke is an emergency where cell death occurs due to ischemia (inadequate blood flow, 87% of cases) or hemorrhage (bleeding, 13%)[1][2]. Interruption of blood flow alters brain metabolism in 30 seconds, stops it in 2 minutes, and causes cell death in 5 minutes[3]. The FAST protocol is critical for rapid recognition: Face drooping, Arm weakness/drift, Speech difficulties, and Time of symptom onset (critical for determining treatment eligibility)[1].

Pathophysiology & Classification

• Ischemic Stroke: Divided into Thrombotic (60% of cases; associated with hypertension, diabetes, and atherosclerosis; symptoms develop slowly/stepwise)[2][6] and Embolic (clot from the heart, often due to atrial fibrillation, travels and occludes a cerebral artery; onset is sudden with severe deficits)[2].
• Hemorrhagic Stroke: Includes Intracerebral (bleeding into brain tissue, mostly caused by hypertension)[2]and Subarachnoid (SAH) (bleeding into CSF-filled space, often from ruptured aneurysms)[9]. SAH can trigger severe vasospasms, peaking 6–10 days post-bleed[10].

Key Diagnostics & Triage Immediate noncontrast head CT or MRI is mandatory to rapidly differentiate ischemic from hemorrhage[4]. The NIH Stroke Scale (NIHSS) (scores 0–42) is the primary clinical tool to document baseline severity and track neurologic changes[11][12].

Acute Interventions & Hemodynamic Targets

• Ischemic: IV tPA must be given within 3 to 4.5 hours of symptom onset after screening out hemorrhage, active bleeding, or recent trauma[13]. Endovascular therapy with stent retrievers is highly effective[14]. Keep BP <185/110 mmHg before tPA, and <180/105 mmHg for 24 hours after[5]. If ineligible for tPA, lower BP only if SBP >220 or DBP >120 mmHg[5].
• Hemorrhagic: Anticoagulants and antiplatelets are strictly contraindicated[14]. Manage hypertension to maintain SBP <160 mmHg[14]. For SAH, administer the calcium channel blocker nimodipine to prevent vasospasm[11][15].

High-Priority Nursing ADPIE Actions

1. Airway & Aspiration: Keep the patient NPO until a formal swallowing screen is completed within 24 hours to prevent aspiration pneumonia[5].
2. ICP Management: Elevate the head of bed 30°, keep head/neck in midline, and avoid hip flexion to maximize venous drainage and reduce intracranial pressure[13][16].
3. Safety & Pattern Recognition: Left-brain stroke causes right hemiplegia, aphasia, slow/cautious behavior, and depression[18]. Right-brain stroke causes left hemiplegia, spatial-perceptual neglect, and highly impulsive, safety-compromising behavior[18][19]. Protect from injury and address one-sided neglect[19][20].
4. VTE Prophylaxis: Implement passive/active range of motion, sequential compression devices, and low-molecular-weight heparin[21].

80/20 Clinical Summary: Renal Failure (AKI vs. CKD)

1. Pathophysiology

• AKI: Sudden, potentially reversible decline in GFR[1].
  • Prerenal: Decreased perfusion (hypovolemia, shock, HF). Oliguria occurs without tissue damage; reversible with fluids[1][2].
  • Intrarenal: Direct tissue damage, 90% from Acute Tubular Necrosis (ATN) (ischemia, sepsis, nephrotoxins)[2].
  • Postrenal: Mechanical obstruction (BPH, calculi) causing urine reflux[3].
• CKD: Gradual, irreversible nephron loss (GFR <60 for >3 months)[4]. Primary causes: Diabetes (50%), Hypertension (25%)[4]. Stage 5 (ESRD) GFR <15[5].

2. Clinical Phases & Manifestations

• AKI Phases:
  • Oliguric (<400 mL/d): Fluid overload (edema, hypertension, pulmonary edema), acidosis, hyperkalemia (ECG: peaked T, wide QRS), and uremia[3][6].
  • Diuretic (1–5+ L/d): Osmotic diuresis (high urea). Risk of hypovolemia, hypotension, hyponatremia, and hypokalemia[7].
  • Recovery: GFR increases, BUN/Creatinine stabilize (takes up to 12 months)[7].
• CKD Manifestations (Uremia):
  • Cardiovascular: Leading cause of death; due to vascular calcification, volume overload, and hypertension[8][9].
  • Hematologic: Anemia from decreased erythropoietin[10].
  • CKD-MBD: Low active Vitamin D reduces calcium absorption[11]. Hypocalcemia triggers PTH release, causing bone demineralization (osteomalacia, osteitis fibrosa) and calcifications[12].

3. Diagnostics & Priority Interventions

• Metrics: GFR is the best indicator of kidney function[8][13]. Creatinine is the best AKI marker[6]. Proteinuria is first sign of CKD[13].
• Hyperkalemia Emergency Care:
  • Cardioprotection: IV Calcium Gluconate (stabilizes myocardium)[14].
  • Shift K+ Intracellularly: IV Regular Insulin + Glucose, or IV Sodium Bicarbonate[14].
  • Definitive Removal: Hemodialysis or Kayexalate (avoid in paralytic ileus due to bowel necrosis)[14][15].
• Fluid Limits: Oliguric AKI: previous 24-hr loss + 600 mL[14].
• Anemia: Exogenous EPO. Monitor for hypertension, clots; supplement iron[16].

4. RRT & Post-Op Care

• HD: Rapid fluid/solute shifts. Assess AV Fistula for thrill and bruit[17]. Safety: No BP/blood draws/IVs in access arm[18]. Complication: Hypotension, cramps[19].
• PD: Uses peritoneal membrane. Core complication: Peritonitis (abdominal pain, rebound tenderness, cloudy effluent)[20][21].
• CRRT: Slow, continuous solute/fluid removal for hemodynamically unstable AKI[22][23].
• Transplantation: Post-op priority is fluid/electrolyte balance[24]. Watch for massive diuresis (replace mL-for-mL) or ATN[24]. CVD is the leading cause of death post-transplant[25].

80/20 Neurological Assessment & Physiology Summary

1. Structure & Cellular Biology

• Organization: The CNS consists of the brain, spinal cord, and CN I-II[1]. The PNS contains CN III-XII, spinal nerves, and the ANS[1].
• Cells & Myelin: Neurons conduct action potentials via saltatory conduction across nodes of Ranvier, accelerated by myelin[2]. Astrocytes form the blood-brain barrier and create scar tissue (gliosis) upon injury[2]. Oligodendrocytes myelinate CNS axons; Schwann cells myelinate PNS axons[2][3].
• Synapses: Neurotransmitters cross synapses to alter impulse transmission, using excitatory (glutamate) or inhibitory (GABA) pathways[4].

2. Pathways, Lobes & Perfusion

• Tracts: Ascending tracts carry sensory input (spinothalamic for pain/temp; dorsal columns for touch, vibration, position)[5]. Descending tracts (corticospinal) carry motor output[5].
• Motor Lesions: UMN lesions cause spasticity, hyperreflexia, and weakness[6]. LMN lesions cause flaccidity, hyporeflexia, and muscle atrophy[6].
• Cerebral Lobes: Frontal lobe controls cognition and motor speech (Broca's)[7]. Parietal lobe senses sensory data[7]. Temporal lobe handles hearing/language (Wernicke's); occipital processes vision[7].
• Perfusion: Anterior circulation stems from carotids; posterior from vertebral-basilar systems, joining at the circle of Willis[8].

3. Bedside Assessment

• Mental Status: Ongoing check of consciousness, orientation, cognition, and mood/affect[9].
• Cranial Nerves: CN III, IV, VI coordinate eye movements[10]. Pupil non-constriction (CN III) is an early sign of brain herniation[10]. Corneal reflex tests CN V/VII[11]. Gag reflex tests CN IX/X; a weak gag risks aspiration[12]. Midline tongue protrusion checks CN XII[12].
• Sensory & Proprioception: Test touch, pain, vibration, and digit position[13][14]. A positive Romberg test indicates posterior column dysfunction[15].
• Reflexes: Deep tendon reflexes are graded 0–5[15]. An extensor plantar response (toes up) signals an abnormal UMN lesion[16].

4. Diagnostics & Nursing Interventions

• CSF Analysis: Normal CSF is clear/colorless, with pressure of 60–150 mm H2O, protein of 15–45 mg/dL, and glucose of 40–70 mg/dL[16].
• Lumbar Puncture (LP) Care: LP is contraindicated in increased ICP due to risk of herniation[17]. Pre-procedure, check coagulation and place the patient in a sitting/side-lying flexed position[18][19]. Post-procedure, keep flat, monitor for headache, and push fluids[18].
• Aging: Aging causes cerebral atrophy, wider ventricles, reduced blood flow, and demyelination[20]. This leads to orthostatic hypotension, poor thermoregulation, and high fall risks[20][21].

Clinician’s 80/20 Hematologic & Anemia Summary

Core Clinical Concepts Blood disorders disrupt homeostasis. Key pathological threads include:

• Fatigue: Secondary to tissue hypoxia (anemia, cancer).
• Infection Risk: Compromised immunity and risk for infection is a major concern in hematologic cancers and a common side effect of therapy.
• Pain: Common and classic in sickle cell disease (SCD) and oncology.
• Perfusion & Clotting: Excessive clotting impairs perfusion; inadequate clotting causes blood loss and fluid volume deficit[1].

Anemia: Definition & Pathophysiology Anemia is not a disease but a manifestation of an underlying pathologic process[2]. It is defined as a deficit in red blood cell (RBC) count, hemoglobin (Hgb) quantity/quality, and/or volume of packed red blood cells (hematocrit)[2]. Tissue hypoxia drives all clinical findings[3]. The body compensates via cardiopulmonary escalation, increasing heart rate (HR) and stroke volume to maintain cardiac output (CO)[4]. Low blood viscosity contributes to systolic murmurs and bruits[4]. If O2 demand exceeds supply, angina or MI occurs[4]. Chronic overwork leads to heart failure (HF), cardiomegaly, congestion, and peripheral edema[4].

Diagnostics & Classification Diagnostics rely on CBC, reticulocyte count, and peripheral smear[2]. Anemia is classified by:

1. Morphology (RBC size/color): Most accurate framework[5].

• Normocytic, Normochromic (MCV 80–95 fL, MCH 27–31 pg): Caused by acute blood loss, hemolysis, CKD, cancers, or SCD[6].
• Microcytic, Hypochromic (MCV <80 fL, MCH <27 pg): Caused by iron deficiency, thalassemia, lead poisoning, B6/copper deficiency[6].
• Macrocytic, Normochromic (MCV >95 fL, MCH >31 pg): Caused by B12 (cobalamin) deficiency, folic acid deficiency, or liver disease[6].

1. Etiology (Cause): Best for structuring care[5]. Divided into decreased RBC production, blood loss, or increased RBC destruction (hereditary like SCD/G6PD vs. acquired like DIC, HELLP, prosthetic valves, or bypass)[7].

Severity & Clinical Manifestations Symptoms depend on onset speed, severity, and Hgb level[3]:

• Mild (Hgb 10–12 g/dL): Often asymptomatic. Heavy exercise triggers compensatory palpitations, mild fatigue, and dyspnea[3].
• Moderate (Hgb 6–10 g/dL): Cardiopulmonary symptoms (dyspnea, palpitations) occur both during activity and at rest[11].
• Severe (Hgb <6 g/dL): Multi-system decompensation occurs[11].
  • Integumentary: Pallor (shunted blood flow), jaundice (bilirubin from RBC hemolysis), and severe itching (accumulation of skin bile)[11].
  • Cardiopulmonary: Marked tachycardia, angina, murmurs, and congestive failure[4].

. DM Classification & Core Diagnostics

• Type 1 DM: Autoimmune β-cell destruction (HLA-DR3/DR4) causing absolute insulin deficiency; presents abruptly with classic 3 Ps (polyuria, polydipsia, polyphagia), weight loss, and DKA risk[1][2].
• Type 2 DM: Insulin resistance combined with relative β-cell deficiency and inappropriate hepatic glucose production[3]. Onset is gradual[4].
• Diagnostic Criteria: A1C ≥6.5%, Fasting Plasma Glucose ≥126 mg/dL, 2-hr OGTT ≥200 mg/dL, or Random Glucose ≥200 mg/dL with classic symptoms[5]. Glycemic target A1C is <7.0%[6].

2. High-Yield Pharmacotherapy & Insulin Dynamics

• Insulin Types: Rapid-acting (lispro, aspart; onset 10–30 min, mealtime bolus), Short-acting (Regular; onset 30–60 min, only IV insulin), Intermediate (NPH; peaks 4–12 hr, cloudy), Long-acting (glargine, detemir; peakless basal)[7].
• Basal-Bolus Strategy: Optimal plan mimicking normal endogenous insulin secretion[7].
• Key Oral Agents: Metformin (Biguanide) reduces hepatic glucose output[10]. Safety Alert: Discontinue metformin 48 hr before/after IV contrast to prevent acute kidney injury and lactic acidosis[10][11]. Sulfonylureas (glipizide) stimulate insulin release and carry high hypoglycemia risk[11][12].

3. Hyperglycemic Emergencies: DKA vs. HHS

• DKA (T1DM): Absolute insulin deficiency → uncontrolled lipolysis → ketone bodies → metabolic acidosis (pH <7.30, HCO₃⁻ <16 mEq/L), Kussmaul respirations, fruity breath, glucose >250 mg/dL[13][14].
• HHS (T2DM): Enough circulating insulin prevents ketosis, but severe hyperglycemia (>600 mg/dL) causes osmotic diuresis, hyperosmolality, and profound neurologic deficits (coma, seizures)[15][16].
• Emergency Treatment Protocol:
  1. IV Fluids: First priority. 0.9% NaCl (1 L/hr) to maintain urine output (30–60 mL/hr)[14][15]. Add 5%–10% dextrose when glucose reaches ~250 mg/dL to prevent hypoglycemia and cerebral edema[14][15].
  2. Potassium: Check K⁺ BEFORE starting insulin. Insulin shifts K⁺ intracellularly, causing life-threatening hypokalemia if uncorrected[15].
  3. Continuous IV Regular Insulin: 0.1 U/kg/hr; target glucose reduction of 36–54 mg/dL/hr[15].

4. Hypoglycemia & Chronic Complications

• Hypoglycemia (<70 mg/dL): Treat via Rule of 15 (15–20g fast-acting carbs, recheck in 15 min)[16][17]. Unconscious: 20–50 mL 50% Dextrose IV or 1 mg Glucagon IM/SQ (turn on side to prevent aspiration)[17].
• Chronic Complications: Driven by angiopathy[18]. Macrovascular (CVD, stroke, PAD) managed via BP (<140/90) and lipid control[19]. Microvascular annual screening: Retinopathy (dilated eye exam), Nephropathy (urine albumin/creatinine; treat with ACEi/ARBs), and Neuropathy (monofilament test, daily foot inspection)[20].

Urinary System: 80/20 Summary

1. Anatomy & Blood Supply The upper urinary tract has two retroperitoneal, bean-shaped kidneys (T12–L3) and 2 ureters[1]. The lower tract comprises the bladder and urethra[1]. Each kidney is shielded by a fibrous capsule and cushioned by fat[1]. The functional unit is the nephron (~1 million), consisting of a glomerulus, Bowman's capsule, and tubule system (PCT, loop of Henle, DCT, and collecting ducts)[2]. Blood flow is ~1200 mL/min (20-25% of cardiac output) via the renal artery, which divides into afferent arterioles[2].

2. Physiology of Urine Formation Urine is formed through filtration, reabsorption, secretion, and excretion[2].

• Glomerular Filtration: Hydrostatic pressure filters blood across a porous, semipermeable membrane into Bowman’s capsule, yielding a filtrate lacking cells and large proteins[3]. Normal Glomerular Filtration Rate (GFR) is ~125 mL/min; only ~1 mL/min is excreted as urine[3].
• Tubular Function:
  • PCT: Reabsorbs 80% of electrolytes and water, all glucose, amino acids, and bicarbonate; secretes H+ and creatinine[4].
  • Loop of Henle: Conserves water and concentrates filtrate. Descending loop is water-permeable; ascending limb actively reabsorbs Cl- and Na+ (25% of sodium load) and is water-impermeable[4].
  • DCT & Collecting Ducts: Finalize regulation of water (controlled by ADH, which increases permeability) and acid-base balance (reabsorbing HCO3- and secreting H+)[4][5]. Aldosterone promotes Na+ and water reabsorption in exchange for K+ excretion[5]. Atrial Natriuretic Peptide (ANP) opposes this by increasing Na+ excretion and GFR[5].

3. Hormonal & Regulatory Functions

• Erythropoietin: Released during hypoxia or hypoperfusion, stimulating RBC production (deficient in renal failure, causing anemia)[5].
• RAAS: Juxtaglomerular cells release renin during hypoperfusion, low BP, or hyponatremia. Renin converts angiotensinogen to angiotensin I, which ACE converts to angiotensin II—causing vasoconstriction and aldosterone release[6].
• Prostaglandins (PGE2, PGI2): Medullary vasodilators that maintain renal blood flow and counteract vasoconstrictors[7].
• Vitamin D: Kidneys perform the final activation step of vitamin D, essential for calcium absorption[5].

4. Diagnostics & Assessment

• Key Labs: Serum creatinine is the most reliable renal function index (released at a constant rate from muscle)[8][9]. Creatinine clearance (24-hr urine) approximates GFR[9][10]. BUN rises with dysfunction but is altered by protein intake, tissue breakdown, and hydration[8].
• Physical Exam: Involves palpation of the right kidney and indirect fist percussion of the costovertebral angle (CVA) to elicit pain in infection or obstruction[11][12].
• Nephrotoxic Risks: Drugs like aminoglycosides, NSAIDs, and contrast media are highly nephrotoxic[13]. Dehydration increases the risk of contrast-induced nephropathy[9].

1. DM Classification & Core Diagnostics

• Type 1 DM: Autoimmune β-cell destruction (HLA-DR3/DR4) causing absolute insulin deficiency; presents abruptly with classic 3 Ps (polyuria, polydipsia, polyphagia), weight loss, and DKA risk[1][2].
• Type 2 DM: Insulin resistance combined with relative β-cell deficiency and inappropriate hepatic glucose production[3]. Onset is gradual[4].
• Diagnostic Criteria: A1C ≥6.5%, Fasting Plasma Glucose ≥126 mg/dL, 2-hr OGTT ≥200 mg/dL, or Random Glucose ≥200 mg/dL with classic symptoms[5]. Glycemic target A1C is <7.0%[6].

2. High-Yield Pharmacotherapy & Insulin Dynamics

• Insulin Types: Rapid-acting (lispro, aspart; onset 10–30 min, mealtime bolus), Short-acting (Regular; onset 30–60 min, only IV insulin), Intermediate (NPH; peaks 4–12 hr, cloudy), Long-acting (glargine, detemir; peakless basal)[7].
• Basal-Bolus Strategy: Optimal plan mimicking normal endogenous insulin secretion[7].
• Key Oral Agents: Metformin (Biguanide) reduces hepatic glucose output[10]. Safety Alert: Discontinue metformin 48 hr before/after IV contrast to prevent acute kidney injury and lactic acidosis[10][11]. Sulfonylureas (glipizide) stimulate insulin release and carry high hypoglycemia risk[11][12].

3. Hyperglycemic Emergencies: DKA vs. HHS

• DKA (T1DM): Absolute insulin deficiency → uncontrolled lipolysis → ketone bodies → metabolic acidosis (pH <7.30, HCO₃⁻ <16 mEq/L), Kussmaul respirations, fruity breath, glucose >250 mg/dL[13][14].
• HHS (T2DM): Enough circulating insulin prevents ketosis, but severe hyperglycemia (>600 mg/dL) causes osmotic diuresis, hyperosmolality, and profound neurologic deficits (coma, seizures)[15][16].
• Emergency Treatment Protocol:
  1. IV Fluids: First priority. 0.9% NaCl (1 L/hr) to maintain urine output (30–60 mL/hr)[14][15]. Add 5%–10% dextrose when glucose reaches ~250 mg/dL to prevent hypoglycemia and cerebral edema[14][15].
  2. Potassium: Check K⁺ BEFORE starting insulin. Insulin shifts K⁺ intracellularly, causing life-threatening hypokalemia if uncorrected[15].
  3. Continuous IV Regular Insulin: 0.1 U/kg/hr; target glucose reduction of 36–54 mg/dL/hr[15].

4. Hypoglycemia & Chronic Complications

• Hypoglycemia (<70 mg/dL): Treat via Rule of 15 (15–20g fast-acting carbs, recheck in 15 min)[16][17]. Unconscious: 20–50 mL 50% Dextrose IV or 1 mg Glucagon IM/SQ (turn on side to prevent aspiration)[17].
• Chronic Complications: Driven by angiopathy[18]. Macrovascular (CVD, stroke, PAD) managed via BP (<140/90) and lipid control[19]. Microvascular annual screening: Retinopathy (dilated eye exam), Nephropathy (urine albumin/creatinine; treat with ACEi/ARBs), and Neuropathy (monofilament test, daily foot inspection)[20].

1. DM Classification & Core Diagnostics

• Type 1 DM: Autoimmune β-cell destruction (HLA-DR3/DR4) causing absolute insulin deficiency; presents abruptly with classic 3 Ps (polyuria, polydipsia, polyphagia), weight loss, and DKA risk[1][2].
• Type 2 DM: Insulin resistance combined with relative β-cell deficiency and inappropriate hepatic glucose production[3]. Onset is gradual[4].
• Diagnostic Criteria: A1C ≥6.5%, Fasting Plasma Glucose ≥126 mg/dL, 2-hr OGTT ≥200 mg/dL, or Random Glucose ≥200 mg/dL with classic symptoms[5]. Glycemic target A1C is <7.0%[6].

2. High-Yield Pharmacotherapy & Insulin Dynamics

• Insulin Types: Rapid-acting (lispro, aspart; onset 10–30 min, mealtime bolus), Short-acting (Regular; onset 30–60 min, only IV insulin), Intermediate (NPH; peaks 4–12 hr, cloudy), Long-acting (glargine, detemir; peakless basal)[7].
• Basal-Bolus Strategy: Optimal plan mimicking normal endogenous insulin secretion[7].
• Key Oral Agents: Metformin (Biguanide) reduces hepatic glucose output[10]. Safety Alert: Discontinue metformin 48 hr before/after IV contrast to prevent acute kidney injury and lactic acidosis[10][11]. Sulfonylureas (glipizide) stimulate insulin release and carry high hypoglycemia risk[11][12].

3. Hyperglycemic Emergencies: DKA vs. HHS

• DKA (T1DM): Absolute insulin deficiency → uncontrolled lipolysis → ketone bodies → metabolic acidosis (pH <7.30, HCO₃⁻ <16 mEq/L), Kussmaul respirations, fruity breath, glucose >250 mg/dL[13][14].
• HHS (T2DM): Enough circulating insulin prevents ketosis, but severe hyperglycemia (>600 mg/dL) causes osmotic diuresis, hyperosmolality, and profound neurologic deficits (coma, seizures)[15][16].
• Emergency Treatment Protocol:
  1. IV Fluids: First priority. 0.9% NaCl (1 L/hr) to maintain urine output (30–60 mL/hr)[14][15]. Add 5%–10% dextrose when glucose reaches ~250 mg/dL to prevent hypoglycemia and cerebral edema[14][15].
  2. Potassium: Check K⁺ BEFORE starting insulin. Insulin shifts K⁺ intracellularly, causing life-threatening hypokalemia if uncorrected[15].
  3. Continuous IV Regular Insulin: 0.1 U/kg/hr; target glucose reduction of 36–54 mg/dL/hr[15].

4. Hypoglycemia & Chronic Complications

• Hypoglycemia (<70 mg/dL): Treat via Rule of 15 (15–20g fast-acting carbs, recheck in 15 min)[16][17]. Unconscious: 20–50 mL 50% Dextrose IV or 1 mg Glucagon IM/SQ (turn on side to prevent aspiration)[17].
• Chronic Complications: Driven by angiopathy[18]. Macrovascular (CVD, stroke, PAD) managed via BP (<140/90) and lipid control[19]. Microvascular annual screening: Retinopathy (dilated eye exam), Nephropathy (urine albumin/creatinine; treat with ACEi/ARBs), and Neuropathy (monofilament test, daily foot inspection)[20].

80/20 Comparative Summary: Amiodarone vs. Lidocaine

1. Class & Mechanism of Action

• Amiodarone (Cordarone): Class III antiarrhythmic with Class I, II, III, and IV actions[1][2]. Primarily blocks potassium channels in phases 2 and 3, delaying repolarization and prolonging effective refractory period[1]. Weakly blocks sodium channels (phase 0 upstroke), depresses SA/AV automaticity, blocks calcium channels, noncompetitively inhibits alpha/beta receptors, and causes vasodilation[2][3].
• Lidocaine: Class IB antiarrhythmic and amide local anesthetic[4]. Selectively inhibits fast sodium channel influx in phase 0, shortening action potential duration and refractory period in His-Purkinje tissue while suppressing automaticity/reentry preferentially in ischemic myocardium[6]. Blocks nerve sodium channels for local anesthesia[7].

2. Indications & ACLS Role

• Amiodarone: Indicated for life-threatening recurrent ventricular fibrillation (VF), hemodynamically unstable ventricular tachycardia (VT), and atrial fibrillation[8]. Used in ACLS CPR for VF/pVT unresponsive to defibrillation[11][12].
• Lidocaine: Indicated IV for acute life-threatening VF/VT (post-MI/cardiac surgery) and ACLS CPR[5][13]. Used topically/regionally for local anesthesia[4][14]. In pediatric ACLS, associated with higher return of spontaneous circulation (ROSC) rates than amiodarone[15][16].

3. Pharmacokinetics & Administration

• Amiodarone: Oral, IV, or IO route[17]. Lipophilic (Vd ~70 L/kg), delayed steady state (1–5 months), and long terminal half-life (mean 53 days)[19][20]. Hepatically metabolized via CYP3A4/2C8 to active metabolite DEA[21]. Dilute in D5W only, use volumetric pumps and in-line filters, and avoid PVC containers/tubing for long infusions due to drug adsorption and DEHP leaching[22].
• Lidocaine: Administered IV, IO, IM, topically, or transdermally[4]. Rapid IV onset (immediate) with short duration (10–20 min)[27]. Hepatically metabolized via CYP1A2/3A4 to MEGX and GX; >98% excreted renally[28][29]. Given as IV bolus load followed by continuous infusion[13][30].

4. Adverse Effects & Safety Warnings

• Amiodarone: Boxed warnings for pulmonary toxicity (up to 17%), fatal hepatotoxicity, and proarrhythmia (QT prolongation, Torsades de Pointes)[31]. Contains ~37% iodine, causing thyroid dysfunction[36]. Causes hypotension, phlebitis (>3 mg/mL), corneal deposits, and photosensitivity[32]. Contraindicated in 2nd/3rd degree AV block, SSS, and severe bradycardia[33].
• Lidocaine: Toxicity causes CNS effects (seizures, confusion, dysarthria) and cardiovascular collapse (bradycardia, hypotension, arrest)[40]. Boxed warning prohibits viscous lidocaine for infant teething pain[44]. Requires 50% infusion rate reduction after 24 hours or in heart failure/hepatic impairment[30].

this is the intro to a new segment comparing two drugs or disease processes to bring you more clarity.

80/20 Summary: Pediatric Cardiac Arrest Recognition & Management

1. Core Pathways & Immediate Recognition (High-Impact 20%)

• Pathways to Arrest: Most pediatric cardiac arrests stem from progressive hypoxic/asphyxial respiratory failure or shock rather than sudden cardiac collapse[1][2]. Out-of-hospital arrest (OHCA) survival is ~8%, whereas in-hospital (IHCA) survival reaches ~43%[1][3].
• Immediate Recognition: Identify unresponsiveness, absent/agonal breathing, and absence of a central pulse assessed in ≤10 seconds[4][5]. Begin CPR immediately within 10 seconds if uncertain[1][5].

2. High-Quality CPR & Airway Management

• Sequence & Ratios: Use C-A-B[6]. Without an advanced airway, compression-to-ventilation ratio is 30:2 (1 rescuer) and 15:2 (2+ rescuers)[7]. With an advanced airway, give continuous compressions at 100–120/min with 1 breath every 6 seconds (10 breaths/min)[7][8].
• Compression Technique: Rate is 100–120/min[7]. Depth is at least 1/3 chest AP diameter (~1.5 in / 4 cm in infants; ~2 in / 5 cm in children)[7]. Allow full recoil and limit chest compression pauses to <10 seconds[7][9]. Rotate compressors every 2 minutes[8][10].
• CPR Monitoring: PETCO₂ goal is >10–15 mmHg; a jump to >40 mmHg indicates Return of Spontaneous Circulation (ROSC)[9][11].

3. Cardiac Arrest Algorithms & Electrical Therapy

• Nonshockable Rhythms (Asystole / PEA): Most common initial pediatric arrest rhythms (~85–95%)[3][5]. Pathway: Start CPR → Give Epinephrine ASAP → Reassess rhythm every 2 minutes → Treat reversible H's & T's[12].
• Shockable Rhythms (VF / pVT): Occurs in 5–15% initially[3]. Pathway: Deliver 1st shock at 2 J/kg → CPR 2 min → Recheck rhythm → If persistent, 2nd shock at 4 J/kg + Epinephrine → CPR 2 min → 3rd shock (≥4 J/kg, max 10 J/kg) + Amiodarone or Lidocaine[10].
• Paddle Sizes: Adult paddles (8–13 cm) for >10 kg (≥1 yr); infant paddles (4.5 cm) for <10 kg (<1 yr)[16].

4. Critical Resuscitation Medications

• Epinephrine: Dose is 0.01 mg/kg (0.1 mL/kg of 0.1 mg/mL) IV/IO every 3–5 minutes[12][17]. ET dose is 0.1 mg/kg[12][17].
• Amiodarone: 5 mg/kg IV/IO bolus (max 300 mg) for refractory VF/pVT, repeatable up to 2 times[12][15].
• Lidocaine: 1 mg/kg IV/IO loading dose[12][15].
• Magnesium Sulfate: 25–50 mg/kg (max 2 g) for Torsades de Pointes or hypomagnesemia[15][18].
• Vascular Access Order: IV → IO (obtain within 30–60 sec) → Endotracheal (ET) as last resort[19][20].

5. Reversible Causes (H's and T's)

• H's: Hypovolemia, Hypoxia, Hydrogen ion (acidosis), Hypoglycemia, Hypo-/Hyperkalemia, Hypothermia[4][21].
• T's: Tension pneumothorax, Tamponade (cardiac), Toxins, Thrombosis (pulmonary), Thrombosis (coronary)[4][21].

80/20 Summary: Pediatric Respiratory Emergency Management

Respiratory failure causes most pediatric cardiac arrests[1]. Prompt management via the Evaluate-Identify-Intervene cycle restores oxygenation and ventilation before collapse[1][2].

1. Core Life-Support & Initial Management

• Rescue Breathing: For respiratory arrest with a pulse, give 12–20 breaths/min (1 breath every 3–5 seconds), each over 1 second for visible chest rise[2]. Reassess pulse every 2 minutes[2].
• Airway Management: Position in comfort or perform head tilt-chin lift (jaw thrust if trauma suspected)[3]. Suction secretions; insert an OPA only if unresponsive without a gag reflex, or an NPA if a gag is present (avoid NPA in facial trauma)[3][4].
• Breathing & Circulation: Provide high-flow O2 via nonrebreathing mask; assist bag-mask ventilation (BMV) if needed[3]. Monitor SpO2, HR, BP, and establish IV/IO access[3].

2. Targeted Management by Etiology Category

Upper Airway Obstruction

• Croup: Mild cases get dexamethasone[5]. Moderate-to-severe require humidified O2, nebulized epinephrine, and dexamethasone[5]. Impending failure needs high-flow O2, BMV, dexamethasone, and ET intubation with a tube 0.5 size smaller[5].
• Anaphylaxis: Give IM epinephrine q10–15 min[6]. Give IV methylprednisolone, albuterol, antihistamines, and 20 mL/kg IV fluid boluses for hypotension[6].
• FBAO: Infants (<1 yr) get 5 back slaps + 5 chest thrusts; children (≥1 yr) get abdominal thrusts[7]. If unresponsive, start CPR; inspect mouth before breaths (no blind finger sweeps)[7].

Lower Airway Obstruction

• Hyperventilation Risks: Avoid hyperventilation during BMV to prevent gastric distension, pneumothorax, and severe air trapping[8].
• Bronchiolitis: Suctioning; bronchodilator trial; O2 for SpO2 < 94%[8].
• Acute Asthma: Give O2, albuterol, and steroids[9]. Severe cases get continuous albuterol, ipratropium, IV steroids, and IV magnesium sulfate[9].

Lung Tissue Disease

• Pneumonia: Give antibiotics within 1 hour, albuterol for wheezing, and CPAP/NIV[10].
• Cardiogenic Edema: Support with PEEP, diuretics, and inotropes[11].
• ARDS: Use permissive hypercapnia, low tidal volume (5–8 mL/kg), and PEEP[12]. Avoid succinylcholine in neuromuscular disease[13].

Disordered Control of Breathing

• Increased ICP: Head midline, avoid hyperventilation (PaCO2 < 30 mmHg causes vasoconstriction), give hypertonic saline/mannitol[14].
• Poisoning: Contact Poison Control, maintain airway, give antidotes (naloxone)[13].

3. Key Takeaways

1. Stabilize ABCs First: Restore oxygenation before advanced therapy[2][3].
2. Select Right Adjunct: OPA for no gag; NPA for intact gag[4].
3. Avoid Over-Ventilation: Prevents barotrauma and reduced cardiac output[8].

80/20 Summary: Pediatric Arrhythmia Management & Algorithms[1]

1. Core Assessment & Stability Principles

• Hemodynamic Instability: Recognized by respiratory failure, shock with poor end-organ perfusion (with or without hypotension), altered mental status/irritability, chest pain, or sudden collapse[1].
• Initial Actions: Support ABCs, give high-concentration O₂, attach ECG/oximetry/BP monitor, obtain IV/IO access, and record a 12-lead ECG without delaying emergency care[1].

2. Pediatric Bradycardia Algorithm (With Pulse & Poor Perfusion)

• Primary Trigger: HR < 60/min with poor perfusion despite adequate oxygenation and ventilation[2][4].
• Immediate Action (CPR): Start high-quality CPR (100–120 compressions/min; depth ≥1/3 AP chest diameter: ~2 in [5 cm] in children, ~1.5 in [4 cm] in infants; complete recoil; minimal interruptions)[2][4].
• Medications for Persistent Bradycardia:
  • Epinephrine: 0.01 mg/kg IO/IV (0.1 mL/kg of 0.1 mg/mL); repeat every 3–5 min. (ET dose: 0.1 mg/kg)[2][5].
  • Atropine: 0.02 mg/kg IO/IV (min 0.1 mg, max single dose 0.5 mg; repeat once in 5 min) for increased vagal tone or primary AV block[2].
  • Cardiac Pacing: Consider for complete AV block or sinus node dysfunction[2][6].
  • Pulseless Arrest: If pulses are lost, switch immediately to the Cardiac Arrest Algorithm[7].

3. Pediatric Tachycardia Algorithm (With Pulse)

Classify by QRS width: Narrow (≤0.09 sec) vs Wide (>0.09 sec)[8][9].

A. Narrow QRS (≤0.09 sec)

• Sinus Tachycardia (ST): HR <220/min (infants) or <180/min (children); P waves present; variable R-R[8][9]. Action: Treat underlying cause (fever, pain, dehydration)[8][9].
• Supraventricular Tachycardia (SVT): HR ≥220/min (infants) or ≥180/min (children); P waves absent/abnormal; abrupt onset[8][9].
  • Stable SVT:
    1. Vagal Maneuvers: Ice bag to upper face (15–20 sec) or straw blowing[10][11].
    2. Adenosine: 0.1 mg/kg IV/IO rapid bolus (max 1st dose: 6 mg) via 2-syringe flush. 2nd dose: 0.2 mg/kg (max: 12 mg)[8][11].
  • Unstable SVT: Synchronized Cardioversion at 0.5–1 J/kg (up to 2 J/kg). If IV/IO available, give adenosine first without delaying shock[12].

B. Wide QRS (>0.09 sec)

• Ventricular Tachycardia (VT):
  • Unstable VT: Synchronized Cardioversion at 0.5–1 J/kg (up to 2 J/kg)[12].
  • Stable VT: Expert consult. Amiodarone 5 mg/kg IV/IO over 20–60 min OR Procainamide 15 mg/kg IV/IO over 30–60 min (do not combine)[15]. Adenosine may be tried if monomorphic[11][13]. Magnesium for Torsades de Pointes[19].

80/20 Core Need-to-Know Principles

• Cardiac Output Formula: Cardiac output equals stroke volume times heart rate ($CO = SV \times HR$)1. Because young children cannot increase stroke volume significantly, bradycardia directly drops cardiac output2.
• Leading Cause of Bradycardia: Tissue hypoxia from hypoxemia or respiratory failure is the main cause of symptomatic bradycardia1. Supporting airway, oxygenation, and ventilation is the initial priority1.
• CPR Threshold: Symptomatic bradycardia is HR < normal for age (typically <60/min) with cardiopulmonary compromise (hypotension, altered mental status, shock)3. If HR stays <60/min with poor perfusion despite ventilation, start CPR immediately3.
• QRS Classification: Tachyarrhythmias are divided by QRS width into narrow ($\le$0.09 s) and wide (>0.09 s)45. Wide QRS tachycardias are assumed to be Ventricular Tachycardia (VT) unless proven otherwise67.

Bradycardia & AV Blocks

• Etiology: Primary bradycardia stems from intrinsic pacemaker/conduction disease (congenital defects, surgery, myocarditis)1. Secondary bradycardia results from noncardiac causes (hypoxia, acidosis, hypotension, hypothermia, drugs)1.
• ECG Features: Slow rate, variable P waves, narrow/wide QRS, and potential AV dissociation2.
• AV Block Spectrum:
  • First-degree: Prolonged PR interval; asymptomatic8.
  • Second-degree Mobitz I (Wenckebach): Progressive PR prolongation until a P wave drops89.
  • Second-degree Mobitz II: Intermittent dropped P waves without PR prolongation (often 2:1 block); risks syncope89.
  • Third-degree (Complete): Complete AV dissociation with independent P waves and QRS complexes; causes fatigue and syncope89.

Tachyarrhythmias: Narrow vs. Wide Complex

• Hemodynamic Impact: Rapid rates shorten diastole, reducing stroke volume and coronary perfusion, causing heart failure and shock4.
• Sinus Tachycardia (ST) vs. SVT:
  • Sinus Tachycardia: Normal response to stress, fever, or hypovolemia5. HR <220/min in infants, <180/min in children5. Shows rate variability, normal P waves, gradual onset5more_horiz.
  • Supraventricular Tachycardia (SVT): Reentry mechanism arrhythmia11. HR $\ge$220/min in infants, $\ge$180/min in children12. Shows abrupt onset, absent/abnormal P waves, constant rate without variability6more_horiz.
• Atrial Flutter: Narrow-complex rhythm with atrial rate >300/min and sawtooth P waves10.
• Ventricular Tachycardia (VT): Wide-complex rhythm (>0.09 s), rate $\ge$120/min, AV dissociation7.
  • Monomorphic VT: Uniform QRS complexes13.
  • Polymorphic VT / Torsades de Pointes: QRS twists around baseline; linked to long QT, hypomagnesemia, hypokalemia, or drugs, deteriorating into VF713.

During the copy past its throwing a lot of weird symbols. I think the information is still helpful

PALS Respiratory Distress & Failure: 80/20 Core Summary

1. Core Pathophysiology & Definitions

• Respiratory Distress: Clinical state with increased respiratory rate and effort (tachypnea, retractions, nasal flaring) while maintaining adequate gas exchange1more_horiz.
• Respiratory Failure: Inadequate oxygenation, ventilation, or both, causing tissue hypoxia and hypercarbia3more_horiz. In pediatrics, failure rapidly leads to cardiac arrest if uncorrected13.
• Hypoxemia: $\text{SpO}_2 < 94\%$ on room air4. Caused by V/Q mismatch, hypoventilation, diffusion defects, or shunts6. Early signs: tachypnea, tachycardia, agitation; late signs: bradypnea, bradycardia, seesaw breathing, lethargy7.
• Hypercarbia: Elevated $\text{PaCO}_2$ resulting in respiratory acidosis5. Lacks visual signs like cyanosis; suspect when agitation converts to decreased consciousness despite oxygen therapy5.

2. Four Clinical Types of Respiratory Problems

• Upper Airway Obstruction (Croup, foreign body aspiration, epiglottitis)8:
  • Key Signs: Inspiratory stridor, barking cough, hoarseness, inspiratory retractions, and poor air entry89.
• Lower Airway Obstruction (Asthma, bronchiolitis)810:
  • Key Signs: Expiratory wheezing, prolonged expiratory phase with active effort, and tachypnea910.
• Lung Tissue Disease (Pneumonia, pulmonary edema, ARDS)10:
  • Key Signs: Grunting (glottic closure maintaining PEEP), crackles (rales), diminished breath sounds, and severe hypoxemia9more_horiz.
• Disordered Control of Breathing (Seizures, head injury, drug overdose)11:
  • Key Signs: Variable/irregular pattern (alternating tachypnea/bradypnea), central apnea, shallow respirations, and altered mental status911.

3. Severity Spectrum: Distress vs. Failure

Early recognition prevents progression from distress to failure and cardiac arrest19:

• Airway Patency: Open and maintainable $\rightarrow$ Not maintainable9.
• Rate & Effort: Tachypnea & increased effort $\rightarrow$ Bradypnea, inadequate effort, or apnea9.
• Air Movement: Good air entry $\rightarrow$ Poor to absent air movement9.
• Heart Rate: Tachycardia (compensatory) $\rightarrow$ Bradycardia (critical late sign of impending arrest)79.
• Skin Appearance: Pallor/mottling $\rightarrow$ Cyanosis3more_horiz.
• Mental Status: Anxiety & agitation $\rightarrow$ Lethargy & unresponsiveness5more_horiz.

4. High-Yield 80/20 Clinical Pearls

• Bradycardia is a Red Flag: Hypoxia-induced bradycardia indicates imminent cardiopulmonary arrest79.
• Grunting Mechanism: Glottic closure during expiration preserves PEEP to prevent alveolar collapse11.
• Decreased Effort $\neq$ Recovery: Reduced work of breathing with depressed mental status signals fatigue and failure39.

. Core Physiology & Definition

• Definition: Shock is inadequate tissue perfusion to meet metabolic demands and oxygenation needs1. Hypotension is not required for diagnosis; shock exists with normal, high, or low SBP1.
• Pediatric Focus: Infants have fixed stroke volume and depend on elevated heart rate to maintain CO3.
• Stroke Volume: Preload (volume), Contractility (pump force), and Afterload (resistance)34.

2. Severity & Compensatory Continuum

• Compensated Shock: Body mechanisms (tachycardia, elevated SVR, venoconstriction) maintain normal SBP despite hypoperfusion56. Key signs: tachycardia, delayed refill, cool skin, oliguria67.
• Hypotensive Shock: Compensatory mechanisms fail, causing low SBP and imminent arrest7. Hypotension is a late finding in most shock types, except septic shock where SVR drops early7.
• Progression: Compensated shock can last hours, but hypotensive shock deteriorates in minutes8.

3. The 4 Shock Types: Differential Pattern Recognition

A. Hypovolemic Shock (Most Common)

• Mechanism: Intravascular volume loss (fluid loss) causing low preload and CO9.
• Signs: "Quiet tachypnea" (rapid breathing without retractions), narrow pulse pressure, pale/cool skin, delayed refill, weak pulses910.

B. Distributive Shock

• Mechanism: Vasodilation causing blood maldistribution and relative hypovolemia110.
• Septic Shock: Commonest form11. Warm Shock: Low SVR, bounding pulses, flushed skin, wide pulse pressure1213. Cold Shock: High SVR, weak pulses, cool skin1213.
• Anaphylactic Shock: Histamine release causes bronchospasm, upper airway edema (stridor), hives, vasodilation14.
• Neurogenic Shock: High spinal injury causes loss of sympathetic tone hypotension without tachycardia (normal HR or bradycardia)15.

C. Cardiogenic Shock

• Mechanism: Primary pump failure with low contractility, high afterload.
• Signs: Tachypnea with increased work of breathing (retractions, grunting, crackles), hepatomegaly, cyanosis1617.

D. Obstructive Shock

• Mechanism: Physical restriction of venous return or cardiac outflow18.
• Tension Pneumothorax: Tracheal deviation, hyperresonance, absent breath sounds19.
• Cardiac Tamponade: Muffled heart sounds, pulsus paradoxus (>10 mmHg SBP drop on inspiration)20.
• Ductal Lesions: Neonatal presentation with differential pre/post-ductal SBP/SpO221.
• Massive PE: Systemic venous congestion and RV failure22.

The PALS Systematic Approach provides a structured framework to quickly evaluate, identify, and treat life-threatening conditions in pediatric cases[1]. Applying the 80/20 principle, clinical priorities focus on rapidly recognizing respiratory failure and shock before cardiac arrest occurs[1][2].

1. Initial Impression (Pediatric Assessment Triangle)

Formed within seconds "from the doorway" without touching the child[1][3]:

• Appearance: Evaluates consciousness, interactiveness, tone, and consolability via TICLS[3].
• Work of Breathing: Identifies respiratory distress via effort (retractions, nasal flaring), position (tripod), and audible sounds (stridor, grunting, wheezing)[3][4].
• Circulation: Assesses systemic perfusion using skin color (pallor, mottling, cyanosis)[3][4].

2. Immediate Life-Threatening Interventions

• Unresponsive, No Breathing/Gasping, No Pulse: Shout for help, activate emergency response, and begin CPR (C-A-B)[5][6].
• Pulse Present, No Breathing: Provide rescue breathing (1 breath every 3-5 seconds; 12-20 breaths/min)[6].
• Pulse <60/min with Poor Perfusion (despite oxygenation): Start chest compressions[5][6].

3. Evaluate-Identify-Intervene Sequence

Care is a continuous loop: Evaluate -> Identify -> Intervene, repeated after every intervention or change in clinical condition[7][8].

4. Primary Assessment (ABCDE Framework)

Rapid hands-on evaluation of vital physiologic functions[7][8]:

• Airway (A): Assess patency (Clear, Maintainable via head tilt-chin lift/jaw thrust/OPA, or Unmaintainable requiring advanced airway)[9].
• Breathing (B): Assess rate (warning: <10 or >60/min)[11], effort, chest expansion (tidal volume 5-7 mL/kg)[12], breath sounds, and SpO2 (hypoxemia: <94%)[13]. Bradypnea and grunting signal impending arrest[14][15].
• Circulation (C): Assess HR (bradycardia is hypoxia-driven)[16], central vs peripheral pulses[17], capillary refill (<=2s)[18], skin color/temp[19], blood pressure (hypotension: infant <70, child 1-10 yrs <70 + 2xage, >10 yrs <90 mmHg)[20], and urine output (infants 1.5-2, children 1 mL/kg/h)[20]. Hypotension signals decompensated shock[20].
• Disability (D): Rapid neuro assessment using AVPU[21] or Pediatric GCS (<=8 indicates severe injury)[22][23], pupil response (PERRL)[24], and blood glucose (hypoglycemia: <=45 mg/dL in neonates, <=60 mg/dL in children)[24].
• Exposure (E): Undress to evaluate trauma, hemorrhage, or petechiae/purpura (indicative of septic shock), preventing hypothermia[24].

5. Secondary Assessment & Diagnostics

• SAMPLE History: Focused history: Signs/symptoms, Allergies, Medications, Past history, Last meal, and Events leading to illness[25].
• Diagnostic Assessments: ABG/VBG (PaO2, PaCO2, pH <7.35 acidosis)[26], blood lactate (tissue ischemia)[27], ScvO2 (normal 70-75%)[28], ECG, and CXR[29].

High-Performance CPR & Perfusion Metrics

• Compressions: Rate 100-120/min at a depth of ≥2 inches (5 cm) with complete chest recoil[1][2].
• Chest Compression Fraction (CCF): Target >80% to maximize coronary perfusion pressure[2][3].
• Capnography (PETCO₂): Continuous waveform monitoring; values <10 mmHg indicate poor CPR quality, whereas an abrupt sustained rise to ≥40 mmHg signals Return of Spontaneous Circulation (ROSC)[1].
• Coronary Perfusion Pressure (CPP): Target CPP (or arterial relaxation pressure) ≥15–20 mmHg to achieve ROSC[2][5].

Adult Cardiac Arrest Algorithm (80/20 Prioritization)

1. VF / Pulseless VT (Shockable Pathway)

• Defibrillation: Immediate 1 shock (Biphasic: 120-200 J; Monophasic: 360 J), then immediately resume CPR for 2 minutes[1][7].
• Epinephrine: 1 mg IV/IO every 3-5 minutes starting after the second shock[1][8].
• Antiarrhythmics: Amiodarone (300 mg IV/IO bolus; 2nd dose 150 mg) or Lidocaine (1–1.5 mg/kg 1st dose; 2nd dose 0.5–0.75 mg/kg) after the third shock for refractory VF/pVT[1][9].

1. PEA / Asystole (Non-Shockable Pathway)

• Immediate Action: No shock. Resume CPR for 2-minute cycles immediately[1][10].
• Epinephrine: 1 mg IV/IO as soon as vascular access is available, repeated every 3-5 minutes[1][11].
• Reversible Causes (H's & T's): Identify and treat Hypovolemia, Hypoxia, Hydrogen ion (acidosis), Hypo-/Hyperkalemia, Hypothermia, Tension pneumothorax, Tamponade (cardiac), Toxins, Pulmonary thrombosis, or Coronary thrombosis[1].

Airway & Ventilation Strategies

• Unadvanced Airway: 30:2 compression-to-ventilation ratio[1][15].
• Advanced Airway: Insert ETT or supraglottic airway; confirm placement with waveform capnography[1].
• Ventilation Rate: 1 breath every 6 seconds (10 breaths/min) with continuous chest compressions[1]. Avoid hyperventilation to prevent reduced venous return[1].

Post-Cardiac Arrest Care (ROSC Management)

• Oxygenation & Ventilation: Titrate FiO₂ for SpO₂ 92–98%; maintain PaCO₂ at 35–45 mmHg[14].
• Hemodynamics: Target SBP >90 mmHg or MAP >65 mmHg using fluid boluses or pressors (Norepinephrine 0.1–0.5 mcg/kg/min, Epinephrine 2–10 mcg/min, or Dopamine 5–20 mcg/kg/min)[14].
• Reperfusion: 12-lead ECG; emergent PCI for STEMI or unstable cardiogenic shock[14].
• Targeted Temperature Management (TTM): If comatose, maintain core temperature at 32-36°C for ≥24 hours[13].

Special Situations

• Pregnancy: Perform manual left lateral uterine displacement; prepare for perimortem cesarean delivery within 5 minutes if no ROSC[17][23].
• LVAD: Check hum/power; perform compressions only if MAP ≤50 mmHg or PETCO₂ ≤20 mmHg and restart fails[24][25].

Core Assessment & Stability Hallmarks

Prioritize identifying whether the rhythm causes hemodynamic instability [1]. Symptomatic bradycardia occurs at HR <50/min [1][4], and symptomatic tachycardia at HR ≥150/min [5][6].

• 5 Instability Signs: Hypotension, altered mental status, signs of shock, ischemic chest discomfort, acute heart failure [2].
• First Actions: Patent airway, assist ventilation/O2 if hypoxemic, monitor/BP/oximetry, IV access, 12-lead ECG [2]. Never delay electrical therapy for a 12-lead ECG in unstable patients [8].

2. Bradycardia Algorithm (HR <50/min)

• Stable: Monitor and observe [2][4].
• Unstable:
  1. Atropine (1st Line): 1 mg IV bolus every 3–5 min (max total: 3 mg) [4][9]. Doses <0.5 mg may slow HR [9].
  2. Atropine Gotchas: Avoid in Mobitz II 2nd-degree or 3rd-degree AV block with wide QRS [9], acute MI [9], or heart transplant patients (Class III: Harm; use TCP/dopamine/epinephrine) [9].
  3. 2nd Line (If Atropine Fails):
  • TCP: Rate 60–80/min; output 2 mA above capture threshold [10]. Sedate conscious patients if possible [11][12]. Contraindicated in severe hypothermia [12]. Don't check carotid pulse for capture [12].
  • Infusions: Dopamine IV (5–20 mcg/kg/min) [2] or Epinephrine IV (2–10 mcg/min) [2].

3. Tachycardia Algorithm (HR ≥150/min)

• Unstable: Immediate Synchronized Cardioversion (consider sedation) [3]. For regular narrow complex, consider Adenosine 6 mg IV [3][6].
• Stable Narrow QRS (<0.12 s):
  1. Regular (SVT): Vagal maneuvers → Adenosine 6 mg IV push + flush [6][14]. If unconverted in 1–2 min, give 12 mg IV [6][14]. Follow with β-blockers or CCBs [6][14]. (Use 3 mg Adenosine in heart transplants/central lines; avoid in asthma/COPD) [14].
  2. Irregular (Afib/Flutter): Rate control with β-blockers or CCBs [14][15].
• Stable Wide QRS (≥0.12 s):
  1. Regular & Monomorphic: Adenosine 6 mg IV only if regular and monomorphic [6][16].
  2. Antiarrhythmic Infusions: Procainamide (20–50 mg/min, max 17 mg/kg; avoid in prolonged QT/CHF) [6][16], Amiodarone (150 mg IV over 10 min) [6][16], or Sotalol (100 mg over 5 min) [6][16].

4. Electrical Therapy & Critical Traps

• Defibrillation (Unsynchronized): Pulseless (VF/pVT), polymorphic VT, or severe deterioration [13].
• Cardioversion (Synchronized): Unstable tachycardia with pulse [13]. Reactivate sync mode after each shock [17].
• AV Nodal Blocker Trap: Do NOT give AV nodal blockers (adenosine, CCBs, β-blockers, digoxin) in pre-excited Afib/flutter (WPW), as it risks triggering VF [14][15]. Avoid combining CCBs and β-blockers due to severe bradycardia [15].

1. Core Epidemiology & Stroke Types

• Ischemic Stroke (87%): Resulting from arterial occlusion; prime candidate for rapid reperfusion therapies (IV alteplase and endovascular therapy)[1].
• Hemorrhagic Stroke (13%): Caused by cerebral vessel rupture; IV fibrinolytics and anticoagulants are strictly contraindicated[1].
• Ischemic Penumbra: Dysfunctional but viable brain tissue surrounding the central infarct core that reperfusion strategies aim to preserve[2][3].

2. Prehospital Assessment & The 8 D's of Stroke Care

• The 8 D's: Detection, Dispatch, Delivery, Door, Data, Decision, Drug/Device, and Disposition[4].
• Prehospital Screening (CPSS): Evaluates Facial Droop, Arm Drift, and Abnormal Speech. A single abnormal finding yields a 72% stroke probability[5].
• Critical EMS Actions: Assess ABCs, check point-of-care blood glucose (treat hypoglycemia <60 mg/dL)[5][6], establish Last Known Normal (LKN) time[5][7], provide hospital prenotification, and bypass ED to CT suite[7][8].

3. In-Hospital Time Targets (NINDS & Target: Stroke)

• Door-to-Assessment: Immediate general assessment within 10 minutes; neurologic exam within 20 minutes[9].
• Door-to-CT/MRI: Noncontrast CT acquired within 20 minutes; expert scan interpretation within 45 minutes[9].
• Door-to-Needle (Alteplase): Administer within 60 minutes of arrival (Target: Stroke III goal: ≥85% within 60 min)[7][9].
• Door-to-Device (EVT): First pass within 90 minutes (direct arrival) or 60 minutes (transfers)[7][9].
• Treatment Windows:
  • IV Alteplase: Within 3 hours (extended to 4.5 hours for select eligible patients)[1].
  • Endovascular Therapy (EVT): Up to 24 hours from onset for confirmed Large Vessel Occlusion (LVO)[9][11].

4. Blood Pressure Thresholds & Pharmacotherapy

• Pre-Alteplase BP Goal: Lower blood pressure to ≤185/110 mmHg before initiating IV alteplase[12].
• Post-Reperfusion Goal: Maintain BP ≤180/105 mmHg for at least 24 hours post-alteplase[12].
• First-Line IV Antihypertensives: Labetalol (10–20 mg IV), Nicardipine (5–15 mg/h IV), or Clevidipine (1–2 mg/h IV)[7][12].

5. Key Contraindications & Stroke System Levels

• Absolute Exclusions: Intracranial Hemorrhage (ICH) on NCCT/MRI[2][13], severe head trauma or ischemic stroke within 3 months[13], prior history of ICH[13], active GI bleed within 21 days[13], or coagulopathy (platelets <100k, INR >1.7, aPTT >40s)[14].
• Stroke Facility Levels: Acute Stroke Ready (ASRH), Primary (PSC), Thrombectomy-Capable (TSC), and Comprehensive Stroke Centers (CSC)[15][16].

Clinical Recognition & Assessment

• Respiratory Arrest Definition: Patient is unconscious and unresponsive with a perfusing pulse, but respirations are absent or inadequate[1]. Agonal gasps do not indicate adequate breathing[1].
• Distress vs. Failure: Normal adult respiration is 12–20 breaths/min with a tidal volume of 6–8 mL/kg[1]. Distress shows tachypnea (>20/min), accessory muscle use, or agitation[1]. Failure is inadequate oxygenation/ventilation marked by severe bradypnea (<12/min), cyanosis, or stupor[1][2]. Rate <6/min requires assisted ventilation with 100% oxygen[1].

2. Ventilation Protocol & Critical Rules

• Ventilation Rate: Deliver 1 breath every 6 seconds (10 breaths/min) using a bag-mask device or advanced airway[3][4]. Deliver each breath over 1 second to produce visible chest rise[3][5].
• Tidal Volume: Provide 500–600 mL (6–7 mL/kg)[2][5]. Adult bag-mask devices often deliver excess volume; caution is advised, and a pediatric bag-mask may be considered[2].
• Pulse Reassessment: Recheck pulse every 2 minutes for 5–10 seconds[3]. If no pulse, start CPR immediately[3].
• Oxygenation Targets: Give 100% oxygen in arrest[1][4]. Maintain SpO2 ≥95% generally, 90% for ACS, and 92–98% for post-cardiac arrest care[4].
• Avoiding Hyperventilation: Excessive ventilation increases intrathoracic pressure, decreases venous return, lowers cardiac output, causes cerebral vasoconstriction, and leads to gastric inflation and aspiration[3].

3. Airway Opening & Adjuncts

• Airway Opening: Tongue displacement due to lost muscle tone is the primary cause of obstruction[4]. Perform head tilt-chin lift, or jaw-thrust without head extension for suspected cervical trauma[4][5].
• Bag-Mask Technique: Two-rescuer BVM using the E-C clamp technique is preferred[5]. Single rescuers should use a pocket mask if available[5].
• OPA (Oropharyngeal Airway): Use only in unresponsive patients without a cough/gag reflex[4][6]. Size from corner of mouth to angle of mandible[6]. Insert curved upward toward palate, then rotate 180°[6].
• NPA (Nasopharyngeal Airway): Suitable for conscious, semiconscious, or unconscious patients[7]. Size length from nose tip to earlobe[7]. Lubricate and insert perpendicular to face[7]. Caution with facial trauma due to cribriform plate fracture risk[7].

4. Suctioning Standards

• Vacuum & Flow: Wall-mounted units must provide >40 L/min airflow and >-300 mmHg vacuum[8].
• Catheter Types: Rigid Yankauer for thick secretions/oropharynx; soft flexible catheter for thin secretions, NPA, or ET tube[8].
• Procedure: Measure catheter and do not insert beyond tongue[8]. Apply suction while withdrawing with a rotating motion, limiting attempts to ≤10 seconds[8].

Rapid Response System (RRT) Triggers

Over half of in-hospital cardiac arrests (IHCAs) stem from respiratory failure or hypovolemic shock[1]. RRS activates based on adult criteria[1]:

• Airway & Breathing: Airway compromise; respiratory rate <6/min or >30/min[1].
• Circulation: Heart rate <40/min or >140/min; SBP <90 mmHg; symptomatic hypertension[1].
• Neurological & Renal: Unexpected drop in consciousness; unexplained agitation; seizures; significant urine output drop[1].
• Subjective: Clinician concern regarding patient deterioration[1].

II. ACS Classification & Triage

The initial 12-lead ECG is central to classifying ACS into two major categories[2]:

1. STEMI: ST elevation in ≥2 contiguous leads (≥2 mm in V2–V3 for men ≥40, ≥2.5 mm for men <40, ≥1.5 mm for women; ≥1 mm in other leads) or new LBBB[4]. Indicates complete coronary occlusion requiring immediate reperfusion[5].
2. NSTE-ACS: ST depression (≥0.5 mm), dynamic T-wave inversion, transient ST elevation, or normal/nondiagnostic ECG[2][4].

III. Initial Medications & Critical Traps

ED assessment within 10 minutes targets ischemia relief and risk triage[3]:

• Aspirin: Administer 162 to 325 mg (chewed) immediately to inhibit COX-1 and thromboxane A2[4][7]. Suppositories (300 mg) for severe nausea/vomiting[7]. Contraindicated in true allergy or active/recent GI bleed[4][7].
• Oxygen: Give (4 L/min) only if SpO2 <90%, dyspneic, hypoxemic, or showing heart failure signs; withhold in normoxic patients[4][7].
• Nitroglycerin: Give 1 sublingual dose every 3–5 minutes (max 3 doses)[7][8]. Contraindications: SBP <90 mmHg (or ≥30 mmHg drop below baseline), severe bradycardia (<50/min), tachycardia (>100/min), or RV infarction[4][7].
• Morphine: IV for pain unalleviated by nitroglycerin; caution in hypotension or RV infarction[4][7]. Can decrease oral antiplatelet absorption[4].
• NSAID Contraindication: NSAIDs (except aspirin) are strictly avoided due to increased risk of mortality, reinfarction, and myocardial rupture[9].

IV. STEMI Reperfusion Timelines

Reperfusion within 12 hours of onset limits myocardial necrosis[5][10]:

• Primary PCI: Preferred strategy[10]. FMC-to-balloon goal ≤90 minutes (≤120 minutes if transferred to PCI facility)[10].
• Fibrinolysis: Door-to-needle goal ≤30 minutes[10]. Most effective within 1 hour of symptom onset (reduces mortality by 47%)[5][10]. Not recommended if symptoms >12 hours; contraindicated >24 hours or for ST depression without posterior MI[8].

V. NSTE-ACS & Adjunctive Care

• High-Risk NSTE-ACS: Early invasive strategy indicated for refractory ischemia, recurrent ST deviation, VT, instability, or heart failure[4][6].
• IV Nitroglycerin: For recurrent ischemia, hypertension, or pulmonary edema; titrate maintaining SBP >90 mmHg[8][11].
• Heparin: Routine adjunct for PCI and fibrinolysis[8].

Fluid Compartments & Homeostasis

• Distribution: Water is 50%–60% of adult weight (varies with fat). ICF holds 2/3 of water; ECF holds 1/3 (interstitial fluid/plasma). Weight change is the best fluid shift indicator (1 kg = 1 L).
• Capillary Exchange: Governed by hydrostatic (pushes out) and plasma oncotic (albumin pulls in) pressures. Edema occurs if hydrostatic pressure rises, oncotic falls, or lymphatics are blocked. Third-spacing traps nonfunctional fluid.

Regulatory Mechanisms

• Hormones: Dehydration triggers thirst and pituitary ADH, raising renal water reabsorption. Aldosterone promotes sodium retention and potassium excretion. Atrial stretch releases natriuretic peptides (ANP/BNP) to excrete sodium/water.

Electrolytes & Clinical Imbalances

• Sodium (136–145 mEq/L): Governs ECF osmolality (280–295 mOsm/kg) and impacts CNS. Hypernatremia (>145 mEq/L) causes cell shrinkage; rapid correction risks cerebral edema. Hyponatremia (<136 mEq/L) causes cell swelling; rapid correction risks osmotic demyelination.
• Potassium (3.5–5.0 mEq/L): Dictates membrane potentials. Hyperkalemia (>5.0 mEq/L) causes peaked T waves, wide QRS, and arrest. Treatment: stop intake, diuretics/binders, shift K+ with insulin/beta-agonists, and stabilize heart with IV calcium. Hypokalemia (<3.5 mEq/L) causes flat T waves, U waves, and weakness. IV KCl must be diluted, infused slowly (<10 mEq/hr), and never pushed.
• Divalent Cations: Calcium (9.0–10.5 mg/dL) is regulated by PTH and calcitonin. Hypercalcemia sedates nerves/muscles; hypocalcemia causes tetany with positive Chvostek/Trousseau signs. Magnesium (1.3–2.1 mEq/L) is vital for ATP. Hypomagnesemia (<1.3 mEq/L) resembles hypocalcemia, causing hyperactive reflexes and torsades.

Acid-Base Balance (pH 7.35–7.45)

Regulated by buffers, lung CO2 excretion, and renal bicarbonate/H+ control:

1. Respiratory Acidosis: Carbonic acid excess from hypoventilation (CO2 retention).
2. Respiratory Alkalosis: Carbonic acid deficit from hyperventilation (CO2 depletion).
3. Metabolic Acidosis: Bicarbonate deficit or acid buildup; anion gap is 8–12 mmol/L.
4. Metabolic Alkalosis: Bicarbonate excess or acid loss (vomiting/NG suction).

Crystalloid Solutions

• Tonicity Effects: Hypotonic (e.g., 0.45% NaCl) dilutes ECF, swelling cells to treat hypernatremia. Isotonic (e.g., 0.9% NaCl, Lactated Ringer's) expands ECF volume without shifts. Hypertonic (e.g., 3.0% NaCl) draws water out of cells to treat hyponatremia.

Fluid Compartments & Homeostasis

• Distribution: Water is 50%–60% of adult weight (varies with fat). ICF holds 2/3 of water; ECF holds 1/3 (interstitial fluid/plasma). Weight change is the best fluid shift indicator (1 kg = 1 L).
• Capillary Exchange: Governed by hydrostatic (pushes out) and plasma oncotic (albumin pulls in) pressures. Edema occurs if hydrostatic pressure rises, oncotic falls, or lymphatics are blocked. Third-spacing traps nonfunctional fluid.

Regulatory Mechanisms

• Hormones: Dehydration triggers thirst and pituitary ADH, raising renal water reabsorption. Aldosterone promotes sodium retention and potassium excretion. Atrial stretch releases natriuretic peptides (ANP/BNP) to excrete sodium/water.

Electrolytes & Clinical Imbalances

• Sodium (136–145 mEq/L): Governs ECF osmolality (280–295 mOsm/kg) and impacts CNS. Hypernatremia (>145 mEq/L) causes cell shrinkage; rapid correction risks cerebral edema. Hyponatremia (<136 mEq/L) causes cell swelling; rapid correction risks osmotic demyelination.
• Potassium (3.5–5.0 mEq/L): Dictates membrane potentials. Hyperkalemia (>5.0 mEq/L) causes peaked T waves, wide QRS, and arrest. Treatment: stop intake, diuretics/binders, shift K+ with insulin/beta-agonists, and stabilize heart with IV calcium. Hypokalemia (<3.5 mEq/L) causes flat T waves, U waves, and weakness. IV KCl must be diluted, infused slowly (<10 mEq/hr), and never pushed.
• Divalent Cations: Calcium (9.0–10.5 mg/dL) is regulated by PTH and calcitonin. Hypercalcemia sedates nerves/muscles; hypocalcemia causes tetany with positive Chvostek/Trousseau signs. Magnesium (1.3–2.1 mEq/L) is vital for ATP. Hypomagnesemia (<1.3 mEq/L) resembles hypocalcemia, causing hyperactive reflexes and torsades.

Acid-Base Balance (pH 7.35–7.45)

Regulated by buffers, lung CO2 excretion, and renal bicarbonate/H+ control:

1. Respiratory Acidosis: Carbonic acid excess from hypoventilation (CO2 retention).
2. Respiratory Alkalosis: Carbonic acid deficit from hyperventilation (CO2 depletion).
3. Metabolic Acidosis: Bicarbonate deficit or acid buildup; anion gap is 8–12 mmol/L.
4. Metabolic Alkalosis: Bicarbonate excess or acid loss (vomiting/NG suction).

Crystalloid Solutions

• Tonicity Effects: Hypotonic (e.g., 0.45% NaCl) dilutes ECF, swelling cells to treat hypernatremia. Isotonic (e.g., 0.9% NaCl, Lactated Ringer's) expands ECF volume without shifts. Hypertonic (e.g., 3.0% NaCl) draws water out of cells to treat hyponatremia.

Acute Respiratory Failure (ARF) and Acute Respiratory Distress Syndrome (ARDS) are critical pulmonary conditions where gas exchange is insufficient to support systemic organs1.

The 80/20 Core: Pathophysiology & Clinical Care

1. Classification of ARF ARF is a symptom of inadequate lung function, categorized into two types12:

• Hypoxemic (Oxygenation Failure): $PaO_2 < 60$ mm Hg on room air2. The core defect is inadequate $O_2$exchange, caused by $V/Q$ mismatch, shunt, diffusion impairment, or alveolar hypoventilation23. Shunt is an extreme mismatch where alveoli fill with fluid, making $O_2$ therapy alone ineffective45.
• Hypercapnic (Ventilatory Failure): $PaCO_2 > 50$ mm Hg with $pH < 7.35$6. It represents insufficient $CO_2$ removal6. Primary causes include CNS depression, neuromuscular disease, chest wall abnormalities, or airway obstruction (COPD, severe asthma)7more_horiz.

2. ARDS Pathophysiology & Phases ARDS is a progressive form of ARF triggered by direct or indirect lung injury11more_horiz. Its hallmark is refractory hypoxemia—unresponsive to supplemental oxygen1415. It progresses in three phases16:

• Injury/Exudative (24–72 hours): Inflammatory mediators damage the membrane, causing edema1617. Alveolar type II cells are damaged, reducing surfactant, which causes collapse (atelectasis) and stiff lungs1819.
• Reparative/Proliferative (1–2 weeks): Fibroblasts and inflammatory cells infiltrate, increasing resistance, causing pulmonary hypertension and decreased compliance20.
• Fibrotic/Late Phase: Diffuse scarring and remodeling further reduce gas exchange surface area, correlating with a poor prognosis21.

3. Interprofessional Management Treatment focuses on treating causes, optimizing gas exchange, and avoiding complications122:

• Ventilation Support: BiPAP decreases the work of breathing (WOB) in mild ARF23. Severe ARDS requires low tidal volume ($V_T$) ventilation (4–8 mL/kg) to prevent barotrauma/volutrauma24. This causes permissive hypercapnia (allowing $PaCO_2$ up to 60 mm Hg if $pH \ge 7.30$)2526. High PEEP is applied to recruit collapsed alveoli27.
• Prone Positioning: For severe ARDS with refractory hypoxemia; turning patients prone recruits dorsal alveoli, improving $V/Q$ matching28.
• Supportive Care: Corticosteroids reduce airway inflammation2930. Fluid management keeps patients "on the dry side" to minimize pulmonary edema31. Enteral nutrition should begin within 24–48 hours to preserve respiratory muscle mass32.

Core Concept: Expiratory Airflow Resistance

Obstructive lung diseases—bronchiectasis, cystic fibrosis (CF), asthma, and COPD—share increased expiratory airflow resistance from airway obstruction or narrowing. Drug therapy plays a key role in their clinical management.

1. Bronchiectasis: Mucus Stasis

• Pathophysiology & Presentation: Inflammation destroys elastic and muscular wall structures, causing permanent dilation and impaired mucus clearance. It presents as a persistent cough with thick, purulent sputum. Massive hemoptysis is a life-threatening complication.
• Care: CT scan is the gold standard. Care involves antibiotics (minimum 14 days), bronchodilators, and ACTs with hydration (2-3 L/day).

2. Cystic Fibrosis (CF): Ion Transport Defect

• Pathophysiology & Presentation: An autosomal recessive CFTR mutation disrupts sodium and chloride transport, producing thick, dehydrated mucus that plugs respiratory, GI, and reproductive ducts. This causes progressive organ scarring, pancreatic insufficiency, and malabsorption.
• Care: Sweat chloride testing is the gold standard. Management relies on aggressive ACTs and mucus-liquefying medications (dornase alfa), combined with pancreatic enzyme replacement before meals and mutation-specific CFTR modulators.

3. Asthma: Reversible Airflow Hyperreactivity

• Pathophysiology & Presentation: Inflammation involves mast cells and eosinophils. Triggers cause an early IgE-mediated bronchospasm, often followed by a late-phase response 4-6 hours later. Signs include wheezing, dyspnea, and cough. A sudden absence of wheezing ("silent chest") is an emergency.
• Care: Spirometry confirms reversibility (>12% and >200 mL FEV1 improvement post-bronchodilator). Inhaled corticosteroids (ICS) are first-line anti-inflammatories, often paired with LABAs. SABAs provide rescue relief, and patients follow an Asthma Action Plan based on peak flow zones.

4. COPD: Progressive Airflow Limitation

• Pathophysiology & Presentation: Non-reversible airflow limitation is driven by chronic exposure to toxins, mainly smoking. Inflammation causes alveolar destruction (emphysema), goblet cell hyperplasia, and loss of elastic recoil. It presents with progressive exertional dyspnea, chronic cough, and a "barrel chest".
• Care: Diagnosed when post-bronchodilator FEV1/FVC is <70%. Key care includes smoking cessation and stepwise inhaled drugs (LAMAs, LABAs, ICS). Calorie-dense nutrition combats cachexia, while pursed-lip breathing reduces air trapping.

This summary distills the 20% of core clinical concepts driving 80% of patient outcomes, grounded directly in the provided material.

1. Lower Respiratory Infections: Pneumonia & Tuberculosis (TB)

• Pneumonia: Acute lung parenchymal infection where pathogens invade via aspiration, inhalation, or blood. Inflammation increases vascular permeability, causing capillary leakage and alveolar fluid consolidation, impairing gas exchange. Clinical Rule: Initiate empiric antibiotic therapy immediately upon suspicion to reduce mortality; adjust only after culture results. Prevent aspiration pneumonia by elevating the head of the bed to ≥30° and checking the gag reflexes.
• Tuberculosis (TB): Airborne disease caused by M. tuberculosis. LTBI vs. Active TB: Latent TB (LTBI) is asymptomatic, non-infectious, has normal chest x-rays, and requires single-drug therapy (e.g., isoniazid). Active TB is infectious, symptomatic, and treated with a 4-drug regimen (isoniazid, rifampin, pyrazinamide, ethambutol). Clinical Priority: Due to the rise of multidrug-resistant strains (MDR-TB), Directly Observed Therapy (DOT) is the standard of care for non-adherent patients.

2. Acute Pleural & Trauma Emergencies

• Tension Pneumothorax: A life-threatening emergency where air enters the pleural space on inspiration but cannot escape, causing positive pressure, lung collapse, and mediastinal shift that compresses the heart and unaffected lung. Manifestations: Severe dyspnea, tachycardia, and tracheal deviation. Requires immediate needle decompression and chest tube insertion.
• Flail Chest: Fracture of ≥3 consecutive ribs in ≥2 places, causing paradoxical chest wall movement (moves inward during inspiration, outward during expiration). Treat with oxygen, analgesics, and positive pressure ventilation to stabilize the segment.

3. Vascular & Blockage Emergencies: Pulmonary Embolism (PE)

• Pathophysiology: Blockage of pulmonary arteries by a thrombus (usually from lower-limb DVT), obstructing alveolar perfusion.
• Diagnosis & Management: Dyspnea is the most common symptom. A spiral CT scan is the gold standard for diagnosis (or V/Q scan if contrast is contraindicated). Key Care: Administer immediate anticoagulation (LMWH or IV heparin) to prevent clot extension; long-term therapy (e.g., warfarin) continues for ≥3 months.

4. Oncologic Malignancies: Lung Cancer

• NSCLC vs. SCLC: Non-Small Cell (84%) grows moderately and is treated surgically if diagnosed in early stages (I–IIIA). Small Cell (SCLC, 13%) is highly aggressive, spreads early via blood and lymph (frequently to the brain), and is treated primarily with systemic chemotherapy and prophylactic cranial irradiation.

I. Oxygen Therapy & Delivery Systems

• Target: Maintain SpO2 >92% (or >88% in chronic COPD) or PaO2 >60 mmHg. Supplementing FiO2 >60% for >24 hours risks oxygen toxicity, causing severe pulmonary edema and inflammatory alveolar damage.
• Low-Flow Systems: Nasal Cannula (1–6 L/min, 24%-44% FiO2), Simple Mask (6–12 L/min, 35%-50% FiO2, requires >=6 L/min), Non-Rebreather (10–15 L/min, 60%-90% FiO2, keep reservoir bag inflated).
• High-Flow Systems: Venturi Mask (delivers precise, fixed FiO2 for COPD), High-Flow Nasal Cannula (up to 60 L/min, 100% FiO2, heated humidification).
• CO2 Narcosis: Some COPD patients lose sensitivity to high CO2, relying on a hypoxic drive to breathe. However, never withhold oxygen during severe, life-threatening hypoxemia.

II. Artificial Airways & Ventilation Modes

• Airways: NPA (used in conscious or unconscious patients) vs. OPA (strictly unconscious patients to avoid vomiting/aspiration). Verify ET tube placement immediately via bilateral breath sounds, symmetric chest movement, and EtCO2 capnography; confirm via chest X-ray (2–3 cm above carina).
• Cuff Management: Keep cuff pressure at 20–30 cm H2O to prevent aspiration and protect tracheal capillary perfusion.
• Ventilation Modes:
  • AC (Assist-Control): Preset rate/VT. Spontaneous breaths get full VT; risks hyperventilation and respiratory alkalosis.
  • PC (Pressure Control): Preset pressure; VT varies. Prevents barotrauma in "stiff" or noncompliant lungs.
  • SIMV: Preset rate/VT; spontaneous breaths vary in volume.
  • PSV (Pressure Support): Preset pressure assisting spontaneous breaths; patient controls rate/VT to facilitate weaning.
• PEEP: Splints open alveoli. High PEEP risks decreased venous return, preload, and cardiac output due to increased thoracic pressure.

III. Nursing Interventions & Complications

• Suctioning: Only PRN (not routinely). Hyperoxygenate with 100% FiO2 before/after; limit passes to <10 seconds. Stop insertion when meeting resistance (carina) to avoid mucosal damage.
• VAP Prevention: Elevate HOB 30–45 degrees, perform daily SAT/SBT trials, provide oral care with Chlorhexidine, and initiate early mobility.
• Unplanned Extubation: Stay with the patient, call for help, and manually ventilate with BVM and 100% O2.
• Accidental Decannulation (Trach <7 days): Spread stoma with hemostat, insert tube with obturator, then remove obturator; if impossible, cover stoma and use BVM over mouth/nose.

IV. Chest Tubes & Drainage Systems

• Water-Seal Chamber: Shows tidaling (water rises on inspiration, falls on expiration). Cessation means lung re-expansion or tube occlusion. Continuous bubbling indicates an air leak.
• Disconnection: Submerge the distal end in sterile water to re-establish a water seal. Never routinely clamp or strip chest tubes.

• Gas Exchange: Primary goal: O2/CO2 exchange across alveolar-capillary membrane12.
• Anatomy: Upper tract warms/humidifies/filters air; epiglottis covers larynx to prevent aspiration3. Carina is highly sensitive, triggering vigorous cough on stimulation3.
• Aspiration: Right mainstem bronchus is shorter, wider, straighter than left; aspiration is far more common in right lung4.
• Dead Space: Normal tidal volume ($V_T$) is ~500 mL (~150 mL is anatomical dead space [$V_D$] without gas exchange)2.
• Alveoli & Surfactant: 300M+ alveoli connect via pores of Kohn2. Surfactant lowers surface tension, preventing collapse (atelectasis)2.
• Pleural Biology: Visceral pleura lacks pain fibers5; parietal pleura has pain fibers, causing sharp pleuritic pain during inflammation5.
• Ventilation: Inspiration is active (diaphragm contracts, drawing air in)56; expiration is passive via elastic recoil6.
• Compliance & Resistance: Compliance decreases in edema, ARDS, fibrosis, and increases in COPD6. Resistance is driven by airway diameter7.
• Control: Central chemoreceptors (medulla) respond to CSF pH/$H^+$ changes; peripheral receptors respond to low $PaO_2$, low pH, high $PaCO_2$7. COPD may rely on hypoxic drive7.
• Defense: Alveolar macrophages provide primary defense below bronchioles8. Smoking impairs their phagocytic activity8.

Gerontologic & Assessment Key Concepts

• Aging: Stiffened chest walls, decreased muscle strength, and fewer elastic alveoli cause early airway closure in lung bases (lower $PaO_2$)9. Decreased cilia, cough force, and pharyngeal sensation raise infection/aspiration risks9.
• Hypoxia Findings: Early signs: restlessness, apprehension, tachycardia, mild hypertension, tachypnea10. Late signs: cyanosis, coma, hypotension, accessory muscle use10.
• Physical Exam:
  • Fremitus: High in pneumonia/edema (dense); low in COPD, pleural effusion1112.
  • Percussion: Normal resonance11; hyperresonance in air trapping (COPD, pneumothorax)1112; dullness in fluid/consolidation (effusion, pneumonia)1112.
  • Sounds: Bronchial (trachea, 2:3 ratio), Bronchovesicular (scapulae, 1:1), Vesicular (periphery, 3:1)13.

High-Yield Diagnostics & Procedures

• Oximetry: Arterial $SpO_2$ (normal >95%) is inaccurate if <70%, or with cold, hypoperfusion, vasopressors14. Venous $SvO_2/ScvO_2$ (normal 60-80%) tracks $O_2$ supply/demand balance1415. Low values show anemia, low cardiac output, high demand1516. High values (sepsis) signal poor tissue extraction1516.
• Procedures:
  • Bronchoscopy: Signed consent, NPO 6-12h before, keep NPO after until gag reflex returns17.
  • Thoracentesis: Done sitting upright leaning on table18; post-procedure chest X-ray checks for pneumothorax1718.

This episode explains what "CC Nurse" means in regards to the podcasts and the episodes

Vancomycin (Vancocin) 80/20 Clinical Summary

1. Core Profile & Mechanism

• Class/Action: Glycopeptide bactericidal antibiotic.
• Mechanism: Binds D-alanyl-D-alanine terminus of peptidoglycan precursors. This inhibits cell-wall synthesis (peptidoglycan polymerase and transpeptidation) and alters permeability, leading to cell death. Also inhibits RNA synthesis.
• Spectrum: Gram-positive pathogens only (Staphylococci, Streptococci, Enterococci). Killing is concentration-independent, requiring an AUC/MIC ratio ≥ 400 for efficacy.

2. Therapeutic Uses & Route Dichotomy

• IV Therapy: Septicemia, endocarditis, skin/skin structure, bone/joint, lower respiratory infections, and surgical prophylaxis.
• Oral Therapy: Strictly for C. difficile-associated diarrhea (CDAD) and S. aureus enterocolitis.
• Route Dichotomy: Oral bioavailability is extremely low. Oral doses are excreted in feces and cannot treat systemic infections. Oral is strictly for local GI action; IV is strictly for systemic infections.

3. Administration & Reconstitution

• IV Infusion Rate: Infuse over ≥ 1 hour (10–15 mg/min) to prevent infusion reactions. Loading doses require 2–3 hours.
• Dilution: Reconstituted vials are diluted with compatible fluids (e.g., D5W, 0.9% NaCl) to 5 mg/mL (up to 10 mg/mL for fluid restriction). Higher concentrations increase reaction risk.
• Oral Solutions: Injection vials can be compounded in water/syrup for enteral/nasogastric use.
• Unlabeled Routes: Rectal enemas for CDAD with ileus; preservative-free intrathecal/intraventricular injections for CNS infections.

4. Adverse Effects & Interactions

• Complications: Nephrotoxicity (renal failure), ototoxicity (hearing loss, tinnitus, vertigo), neutropenia, thrombocytopenia, SJS/TEN, DRESS, and anaphylactoid reactions.
• Infusion Reaction: Rapid IV infusion causes histamine release, leading to hypotension, dyspnea, flushing, pruritus, and urticaria. Manage by stopping or slowing the infusion.
• Interactions: Synergistic toxicity with aminoglycosides. Histamine-inducing drugs (ciprofloxacin, opioids, propofol) can hinder desensitization.

5. Monitoring & Interventions (The "20%" Core)

• Therapeutic Drug Monitoring (TDM): Mandatory for IV therapy. Trough levels of 15–20 mg/L target a therapeutic AUC/MIC of 400–600.
• Renal Adjustments: Extend IV intervals in renal impairment based on CrCl or SCr to avoid drug accumulation.
• Key Interventions: Monitor renal function (SCr, BUN), urine output, and auditory symptoms. Assess IV site frequently for phlebitis.

Lanoxin (Digoxin) 80/20 Clinical Summary

1. Expected Action & Mechanism

• Positive Inotrope: Inhibits the Na+/K+-ATPase pump1, raising intracellular sodium. This reverses sodium-calcium exchange to increase intracellular calcium, boosting myocardial contractility, force, and velocity12.
• Negative Chrono/Dromotrope: Increases vagal activity, slowing AV nodal conduction and prolonging refractory period to slow ventricular rate3.

2. Therapeutic Use & Selection

• Indicated for heart failure (HF) and controlling ventricular rate in chronic atrial fibrillation (AF)4. Off-label for fetal supraventricular tachyarrhythmias5.
• Benefit: Boosts cardiac output, lowers sympathetic tone/heart rate, and causes diuresis2. Beta-blockers, verapamil, and diltiazem are replacing it for AF rate control13. Does not convert acute AF to sinus3.

3. Crucial Administration Protocols

• IV: Preferred (IM causes severe pain)67. Dilute 1 mL in $\ge$4 mL sterile water, 0.9% NaCl, or D5W to prevent precipitation8. Inject slowly over $\ge$5 minutes to avoid sudden vasoconstriction8.
• Oral (PO): Tablet bioavailability is 60–80% (solution 70–85%)910. High-fiber meals decrease absorption910.

4. Dosing & Renal Safety Guidance

• Dosing must be based on lean body weight (LBW), efficacy, and serum levels4.
• Geriatric: PIM (avoid first-line); if used, limit to 125 mcg/day to reduce toxicity risk1112.
• Renal GFR Adjustments (Half-life 36–48h)13:
  • >50 mL/min: No adjustment14.
  • 10–50 mL/min: Give 25%–75% of dose every 36h14.
  • <10 mL/min: Give 10%–25% of dose every 48h14.
  • Dialysis: Not removed by dialysis15.

5. Adverse Reactions & Toxicity

• Severe Risks: AV block, bradycardia, VT/VF, cardiac arrest, hyperkalemia, bowel ischemia/necrosis1617.
• Toxicity Signs: Blurred/yellow vision (xanthopsia), GI distress (nausea, vomiting, anorexia), and CNS changes (confusion, delirium, hallucinations)16more_horiz.

6. Priority Nursing Pearls (The 20% to Know)

• Monitoring: Track heart rate (bradycardia risk)16, toxicity, and clinical efficacy4.
• Labs: Monitor GFR/CrCl, potassium (hypokalemia is an adverse reaction; hyperkalemia occurs in toxicity), and digoxin levels16more_horiz.
• Interactions: Digoxin is a P-gp substrate; P-gp inhibitors/inducers trigger drug interactions13. WPW use increases ventricular response risk4.

Description & Key Indications: Albuterol is a short-acting beta-2 agonist (SABA) used as an inhaled bronchodilating agent. It treats acute bronchospasm and episodic wheezing in asthma, exercise-induced bronchospasm (EIB) prophylaxis, and serves as reliever therapy in COPD. Off-label uses include hyperkalemia, where it lowers potassium by 1–1.5 mEq/L, and managing respiratory symptoms in anaphylaxis unresponsive to epinephrine. Inhaled albuterol is preferred over oral routes due to its superior side-effect profile and faster onset.

Mechanism of Action: As a racemic mixture, bronchodilation is driven by the R-isomer (levalbuterol); the S-isomer exhibits bronchoconstrictive properties in animals. Albuterol stimulates moderately selective beta-2 receptors, activating adenylate cyclase to increase intracellular cyclic AMP. This triggers protein kinase A, inhibiting myosin phosphorylation and lowering calcium to relax bronchial smooth muscle. It also inhibits mast cell degranulation and drives potassium intracellularly via the Na/K ATPase pump.

Crucial Safety & Adverse Effects: Inhalation avoids many systemic issues, but severe reactions can occur, including paradoxical bronchospasm, arrhythmia, atrial fibrillation, Stevens-Johnson syndrome, and anaphylactoid reactions. Common mild-to-moderate effects include tremors (to 37.9%), infections (to 21%), headaches, rhinitis, tachycardia, palpitations, hypokalemia, and excitability.

Remaining 80% (Administration, Dosages & Pharmacokinetics)

Administration Techniques: Inhalation methods include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. MDIs require shaking, priming, and slow inhalation, followed by a 10-second breath hold; spacers or valved holding chambers (VHC) are recommended for pediatric and uncoordinated patients. For pediatric acute asthma, MDI with a VHC is as effective as nebulization. DPIs (e.g., RespiClick) are breath-activated upon opening the cap and must remain dry at all times. Nebulized solution is delivered over 5 to 15 minutes; "blow-by" is discouraged.

Dosing Standards: For acute asthma exacerbations, adults and children age 6 and older inhale 360–900 mcg via MDI every 20 minutes for the first hour, then every 1 to 4 hours as needed. EIB prophylaxis requires 180 mcg inhaled 15–30 minutes before exercise. Oral doses range from 2–4 mg 3–4 times daily, but guidelines discourage this route due to slow onset and systemic side effects.

Pharmacokinetics: Inhaled albuterol works within 5–15 minutes, peaks in 0.5–2 hours, and lasts 2–6 hours, with 90% of the dose typically swallowed. Oral immediate-release onset is 30 minutes, lasting 4–6 hours, while extended-release lasts 8–12 hours. Metabolism is hepatic, and excretion is primarily renal.

• Dose-Dependent Mechanism: Dopamine is a metabolic precursor to norepinephrine. Clinical effects depend entirely on the infusion rate:
  • Low Dose (< 5 mcg/kg/min): Stimulates dopaminergic D1 and D2 receptors in renal, mesenteric, coronary, and cerebral beds, causing vasodilation and increasing blood flow.
  • Intermediate Dose (5 to 10 mcg/kg/min): Stimulates dopaminergic and beta-1-receptors, increasing cardiac contractility, chronotropy, and mildly raising systemic vascular resistance.
  • High Dose (> 10 mcg/kg/min): Stimulates alpha-receptors, causing potent vasoconstriction. Rates > 20 mcg/kg/min frequently cause arrhythmias or severe vasoconstriction.
• Key Indications: Dopamine provides hemodynamic support in distributive shock (e.g., septic, cardiogenic, anaphylactic, neurogenic), open-heart surgery, or renal failure. It is used for symptomatic bradycardia unresponsive to atropine or pacing, and post-cardiac arrest hypotension. It can provide short-term inotropic support in acute/chronic heart failure.
• Black Box Warning (Extravasation): Extravasation can cause severe tissue necrosis. Dopamine must be infused into a large vein (e.g., antecubital fossa). If extravasation occurs, immediately infiltrate the area with 10 to 15 mL of 0.9% NaCl containing 5 to 10 mg of phentolamine using a fine needle.

The Supporting 80% (Operational Details)

• Administration & Incompatibilities: Correct hypovolemia before starting. Dilute concentrate in compatible solutions (e.g., 5% Dextrose, 0.9% NaCl) to 200–1,600 mcg/mL (standard adult infusions use 1,600 or 3,200 mcg/mL). It is completely inactivated in alkaline solutions; never add to Sodium Bicarbonate. Do not run dextrose-containing dopamine through the same line as blood to prevent hemolysis. Monitor urine flow, cardiac output, and blood pressure.
• Dosing:
  • Adults: Initially 2 to 5 mcg/kg/min, titrating by 5 to 10 mcg/kg/min (Max: 50 mcg/kg/min).
  • Pediatrics (Neonates to Adolescents): Initially 1 to 5 mcg/kg/min, titrating by 2.5 to 5 mcg/kg/min (Max: 15 to 20 mcg/kg/min).
• Pharmacokinetics: Administered via IV or intraosseously (during CPR). Onset is within 5 minutes, persisting under 10 minutes, with a 2-minute plasma half-life. It does not cross the blood-brain barrier significantly and is metabolized in liver, kidneys, and plasma by MAO and COMT. About 25% is converted to norepinephrine. Excreted in urine.

Zosyn (Piperacillin/Tazobactam) 80/20 Clinical Summary

Core Classification & Mechanism

• Drug Class: Zosyn is an injectable combination of piperacillin (extended-spectrum penicillin) and tazobactam (beta-lactamase inhibitor).
• Bactericidal Action: Piperacillin binds to penicillin-binding proteins (PBPs), inhibiting cell wall synthesis and causing autolysin-mediated lysis.
• Beta-Lactamase Protection: Tazobactam is an irreversible inhibitor of beta-lactamases (Sykes types II–V, staphylococcal penicillinase, and ESBLs), shielding piperacillin.
• Pharmacodynamics: Exhibits time-dependent (concentration-independent) killing, relying on time free drug levels remain above the pathogen's MIC.

Pharmacokinetics & Delivery

• Administration: Given via IV infusion over at least 30 minutes or via extended (4-hour) / continuous (24-hour) infusions. It is not FDA-approved for IV push.
• Distribution: Widely distributed in tissues (50–100% of plasma); both drugs are ~30% protein-bound.
• Elimination: Cleared unchanged in urine (68% piperacillin, 80% tazobactam) via tubular secretion/glomerular filtration. Half-life is 0.7–1.5 hours in normal renal function.

High-Yield Indications & Adult Dosing

• Skin/Skin Structure: 3.375 g IV every 6 to 8 hours (for 5 to 14 days).
• Intra-abdominal: 3.375 g IV every 4 to 6 hours or 4.5 g IV every 6 hours.
• Nosocomial Pneumonia: 4.5 g IV every 6 hours (for 7 to 14 days).
• Sepsis/Bacteremia & Febrile Neutropenia: 4.5 g IV every 6 hours.

Renal & Hepatic Adjustments

• Hepatic Impairment: No dose adjustment needed.
• Renal Impairment (Conventional Adult Dosing):
  • CrCl > 40 mL/min: No adjustment.
  • CrCl 20 to 40 mL/min: Nosocomial pneumonia reduced to 3.375 g every 6 hours; other indications reduced to 2.25 g every 6 hours.
  • CrCl < 20 mL/min: Nosocomial pneumonia reduced to 2.25 g every 6 hours; other indications reduced to 2.25 g every 8 hours.
  • Hemodialysis: Max 2.25 g every 8 hours (pneumonia) or 12 hours (others); give a 0.75 g to 1.125 g supplemental dose post-dialysis as 30–40% is cleared.

Key Safety & Adverse Reactions

• Common: Diarrhea (11.3–20.0%), headache, nausea (5.8–6.9%), and constipation (7.7–8.4%).
• Severe Risks: Anaphylactic shock, acute renal failure, seizures, and C. difficile-associated diarrhea.
• Hematologic Warnings: Leukopenia, thrombocytopenia, platelet dysfunction, and prolonged bleeding times.
• Cutaneous Reactions: Stevens-Johnson syndrome, TEN, and DRESS.

Amiodarone (Cordarone) Clinical 80/20 Summary

1. Mechanism & Physiological Effects (The 20% Science)

• Multiclass Action: Class III antiarrhythmic (potassium blocker delaying phase 2/3 repolarization and prolonging refractory period). Also exhibits Class I (sodium blockade slowing phase 0), Class II (noncompetitive alpha/beta-blockade), and Class IV (calcium blockade) properties.
• Hemodynamics: Relaxes smooth/cardiac muscle, decreasing peripheral/coronary vascular resistance and afterload, reducing myocardial oxygen demand (MVO2).

2. Clinical Uses & Key Dosing

• Ventricular Arrhythmias (ACLS): For pulseless VF/VT: 300 mg IV/IO push, then 150 mg if refractory.
• Stable VT / Wide-Complex Tachycardia: 150 mg IV over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min maintenance.
• Atrial Fibrillation/Flutter (Off-Label): Rate control and conversion.
• Oral Dosing: Slow absorption and massive tissue distribution require large loading (800–1600 mg/day for 1–3 weeks) before maintenance of 200–400 mg/day.

3. Critical Toxicities & Warnings (The High-Risk 20%)

• Pulmonary Toxicity: Fatal pneumonitis or alveolar/pulmonary fibrosis (up to 17% incidence; 10% mortality). Monitor baseline and regular PFTs and chest X-rays.
• Hepatotoxicity: Can cause severe liver injury. Monitor transaminases; hold or reduce dose if LFTs exceed 3x upper limit of normal.
• Thyroid Dysfunction: Amiodarone is 37% iodine by weight and blocks T4-to-T3 conversion. Can cause hypo- or hyperthyroidism (thyrotoxicosis). Monitor TSH.
• Cardiotoxicity: Bradycardia, AV blocks, and QT prolongation leading to Torsade de Pointes. Contraindicated in sick sinus syndrome and 2nd/3rd-degree block without a pacemaker.
• Ocular/Dermatologic: Corneal microdeposits (common), photosensitivity, and blue-gray skin discoloration.

4. Nursing & Administration Pearls

• Infusion Safety: Concentrations >2 mg/mL cause severe phlebitis; use a central line for infusions >1 hour. Always use an in-line filter and volumetric pump.
• Incompatibility: Adsorbs to PVC (dosing accounts for this) and leaches toxic DEHP plasticizers from PVC tubing. Use glass or polyolefin containers for infusions >2 hours.
• Pharmacokinetics: Highly lipophilic; volume of distribution is ~70 L/kg. Terminal half-life averages 53 days (range 26–107 days). Effects and interactions (inhibits CYP3A4, CYP2C9, P-gp) persist for months after stopping.
• Client Education: Take consistently with/without food. Report new dyspnea or cough immediately. Wear sunscreen. Follow up for ophthalmic, thyroid, and liver testing.

Epinephrine is a potent, nonselective adrenergic agonist acting on alpha-1, alpha-2, beta-1, and beta-2 receptors. This high-yield 80/20 summary covers the essential clinical and exam concepts:

1. Expected Pharmacological Action & Mechanism

• Alpha-1 activation causes arteriolar vasoconstriction.
• Beta-1 activation induces positive inotropic and chronotropic responses, increasing cardiac workload and coronary vasodilation.
• Beta-2 activation drives bronchodilation, skeletal muscle vasodilation, and hepatic glycogenolysis.
• Alpha-2 activation inhibits insulin release and provides negative feedback on norepinephrine.
• Actions are mediated by cyclic AMP (increased by beta, decreased by alpha).

2. Clinical Indications & Route Optimization

• Anaphylaxis: Drug of choice. Intramuscular (IM) injection in the anterolateral thigh (vastus lateralis) is preferred because absorption is rapid and complete. Subcutaneous (SQ) absorption is delayed and variable, making it not routinely recommended.
• Cardiac Arrest: Administer 1 mg IV or IO every 3 to 5 minutes. Do not interrupt CPR to administer. Flush with 0.9% NaCl to promote central entry.
• Hemodynamic Support: Continuous IV infusion at 0.01 to 2 mcg/kg/min. Low doses (<0.3 mcg/kg/min) favor beta-effects (tachycardia, inotropy, decreased SVR), while higher doses (>0.3 mcg/kg/min) cause alpha-vasoconstriction.
• Endotracheal (ET): Used only if IV/IO is delayed. Requires higher doses (e.g., 2 to 2.5 mg in adults) and is associated with lower drug levels and survival.

3. Safety, Administration & Nursing Interventions

• Extravasation Antidote: Extravasation causes severe ischemia and tissue necrosis. Avoid peripheral leg veins in the elderly. Immediately infiltrate the cold, pale area with phentolamine (5 to 10 mg in 10 to 15 mL saline for adults).
• Incompatibilities: Epinephrine is inactivated in alkaline solutions and is incompatible with sodium bicarbonate. Protect from light; discard if cloudy, pinkish, or brownish.
• Metabolic Tracking: Monitor for transient hyperkalemia followed by hypokalemia (due to potassium uptake into skeletal muscles), and hyperglycemia (due to insulin inhibition and glycogenolysis).
• Complications: Watch for severe reactions including stroke, myocardial infarction, ventricular fibrillation/tachycardia, pulmonary edema, and severe hypertension.

Clinical Action & Pharmacokinetics

• Mechanism: Propofol is an IV anesthetic/sedative that enhances GABAA currents by slowing deactivation and reducing receptor desensitization. It also inhibits NMDA glutamate receptors, depressing excitatory transmission, and exerts antiemetic effects by reducing serotonin in the area postrema.
• Pharmacokinetics: Follows a 3-compartment linear model. Onset is rapid (~40s) via quick blood-brain equilibration. Clearance is 23–50 mL/kg/min via hepatic conjugation to inactive metabolites excreted by kidneys. Distribution accounts for 50% of plasma decline. Infusions over 10 days accumulate in fat, extending terminal half-life to 1–3 days and delaying recovery.

Critical Administration & Dosing Rules

• Safe Handling: It is a single-use product; maintain strict aseptic technique. Discard unused propofol or tubing within 12 hours of opening, or within 6 hours if mixed with lidocaine. Do not administer Fresenius Propoven via a microbiological filter.
• Induction Dosing (IV):
  • Healthy Adults (18–64): 2 to 2.5 mg/kg IV titrated to response.
  • Geriatric/Debilitated/ASA III/IV: 1 to 1.5 mg/kg IV.
  • Pediatric (3–16): 2.5 to 3.5 mg/kg IV.
• Maintenance & ICU Sedation:
  • Anesthesia Maintenance: 50 to 100 mcg/kg/min continuous IV infusion after a 150–200 mcg/kg/min loading phase.
  • ICU Sedation (Ventilated Adults): Start at 5 mcg/kg/min; titrate by 5–10 mcg/kg/min every 5–10 minutes (usual range: 5–50 mcg/kg/min). Do not exceed 4 mg/kg/hour unless benefits outweigh risks.
  • Discontinuation: Avoid abrupt withdrawal to prevent rapid awakening, anxiety, and ventilator resistance; maintain light sedation until 10–15 minutes before extubation.
• Pain Reduction: Administer via larger veins, or add IV lidocaine (up to 20 mg per 200 mg propofol) immediately before injection.

Major Safety Warnings & Complications

• Provider Requirements: Administer only by clinicians trained in general anesthesia or critical care, with immediate access to airway, ventilation, and resuscitation equipment. Lock/manage inventory to prevent diversion.
• Adverse Reactions:
  • Cardiovascular & Respiratory: Hypotension is highly common (3% to 26%). Other risks include bradycardia (1% to 3%), apnea (1% to 3%), respiratory depression, hypoxia, and pulmonary edema.
  • PRIS: Prolonged, high-dose infusions for ICU sedation are associated with Propofol-Related Infusion Syndrome (PRIS), causing fatal metabolic derangements and organ failure.
  • EUA Warning: Fresenius Propoven 2% is double the strength (20 mg/mL) of standard FDA-approved 1% (10 mg/mL). Exercise extreme caution with pump settings to prevent overdose.

Norepinephrine (Levophed) 80/20 Summary

• Action & MOA: Direct α-agonist causing potent vasoconstriction. Modest β1​ activity triggers cardiac stimulation at lower doses; vasoconstriction dominates at higher doses. Elevated SVR triggers reflex vagal bradycardia (slowing HR). Coronary flow increases without raising myocardial oxygen demand.
• Uses: First-line for septic shock, sepsis, acute hypotension, cardiogenic shock. Alternative in hepatorenal syndrome (with albumin).
• Complications: Tissue necrosis (extravasation), bradycardia, lactic acidosis, pulmonary edema, hypertension, and local hypoxia.
• Administration & Dilution:
  • Dilution: Standard: 4mg in 1,000mL. Preferred: D5W/D5NS (dextrose protects against oxidation). Saline alone stable up to 16mcg/mL, though FDA discourages. Adult standard: 16, 32, 128mcg/mL.
  • Incompatibility: Do not mix with alkaline solutions (e.g., bicarb). Reject if pinkish/discolored or has precipitate.
  • Route: Large vein infusion; transition to central line ASAP. Avoid leg veins in elderly.
  • Monitoring: BP every 2 mins initially, then every 5 mins. Check site frequently for free flow/extravasation.
  • Weaning: Reduce rate gradually; avoid abrupt withdrawal to prevent rebound hypotension.
• Extravasation Antidote: Infiltrate ASAP (within 12h) with phentolamine 5-10mg in 10-15mL NS.
• Pharmacokinetics: Onset <30s; steady-state 5 mins; duration <10 mins. Half-life ~2.4 mins; metabolized by COMT/MAO.
• Why Choose It? Preferred in septic shock; raises MAP/SVR with less tachycardia than dopamine, sparing oxygen demand.

Final 80/20 Review

• The 20% to Absolutely Know:
  1. Hypovolemia First: Correct fluid deficit before starting norepinephrine.
  2. Central Line Priority: Transition to central line ASAP to mitigate necrosis risk.
  3. Phentolamine for Extravasation: Immediate local infiltration reverses ischemia.
  4. Dextrose Over Saline: Dextrose-containing diluents prevent oxidation.
  5. Incompatible with Bicarb: Inactivated in alkaline solutions.
• If I Remember Nothing Else: Norepinephrine is the first-line vasopressor for septic shock. With a <30s onset and 2.4m half-life, it requires continuous infusion, BP checks every 2–5 mins, and gradual weaning. Monitor the IV site continuously; treat extravasation with immediate phentolamine infiltration to prevent necrosis.

Vasopressin (Vasostrict) Clinical Reference

1. Action: Exogenous ADH analog. Promotes renal water reabsorption via cAMP. Directly contracts vascular smooth muscle non-adrenergically. 2. Use: Raising BP in vasodilatory shock refractory to fluids/catecholamines; post-op abdominal distention. 3. Complications: Cardiac arrest, bradycardia, MI, AFib, water intoxication, severe hyponatremia, necrosis. 4. Admin: IV infusion must go through central vein. If peripheral, use >=20G catheter & check frequently. Premixed (0.4/0.6 units/mL) needs no dilution. Dilute 20 units/mL to 0.1 or 1 unit/mL in NS/D5W. Discard after 18h room temp, 24h refrigerated. IM/SC duration is 2-8h; IO used in CPR. 5. Contraindications: No renal/hepatic adjustments needed. Caution in coronary artery disease (ischemia risk). 6. Nursing: Monitor ECG, BP, fluids, sites. For extravasation, inject 5-10 mg phentolamine directly. 7. Interactions: Muscle contraction not blocked by adrenergic blockers/denervation. No CYP450 interactions. 8. Education: ICU drug; explain central line need and to report chest pain or IV burning. 9. Evaluation: Increased MAP, catecholamine-sparing, stable sodium/osmolality. 10. Why Choose? Bypasses catecholamine resistance. Onset peaks <15 min; fades <20 min of stopping. 11. Pearls:

• Most Dangerous: MI, tissue necrosis.
• Key Lab: Serum sodium (detects hyponatremia).
• Antidote: Phentolamine 5-10 mg for extravasation.
• NCLEX/ATI: Run through central line to prevent necrosis. 12. Scenario: Septic shock patient hypotensive on norepinephrine. Adding vasopressin raises MAP, allowing down-titration of toxic catecholamines. 13. Mnemonic: Vasopressin Presses Vessels (V1 constriction) & Preserves Volume (V2 reabsorption).

THE 20% I ABSOLUTELY NEED TO KNOW

• Catecholamine-Saver: Works on non-adrenergic receptors, maintaining potency in severe acidotic shock where catecholamine receptors are down-regulated.
• Extravasation Rescue: High necrosis risk peripherally. Immediately inject 5-10 mg phentolamine to site if extravasation occurs.
• Water Retention: Exogenous ADH action causes renal water retention, causing dilutional hyponatremia/water intoxication.

IF I REMEMBER NOTHING ELSE

1. Direct non-adrenergic vasoconstrictor with strong catecholamine-sparing effect.
2. IV onset peaks <15 min; pressor effects fade <20 min of stopping.
3. Central line infusion preferred; extravasation causes severe skin necrosis.
4. Phentolamine (5-10 mg) is the antidote for local extravasation.
5. Conserves free water; monitor closely for hyponatremia.
6. No hepatic or renal dosage adjustments are required.

Vecuronium is an intermediate-acting, nondepolarizing neuromuscular blocking agent used for skeletal muscle relaxation during surgery, mechanical ventilation, and endotracheal intubation, including rapid-sequence intubation (RSI).

1. Critical Safety & Boxed Warning (The Vital 20%)

• Respiratory Paralysis: Causes respiratory paralysis (potentially fatal). Administer only by experienced clinicians in settings with immediate intubation, ventilation, oxygen, and reversal agents.
• Induction Prerequisite: To prevent extreme distress, vecuronium must only be administered after unconsciousness is induced with adequate amnesia, sedation, and analgesia.
• Storage Warning: Due to risk of fatal accidental administration, store vials with cap/ferrule intact and separated from other drugs to prevent selection errors.

2. Mechanism of Action & Pharmacokinetics

• Mechanism: Competes with acetylcholine (ACh) for receptors at the motor end-plate. Paralysis progresses predictably: fine muscles (eyes, face, neck) first, then limbs, chest, abdomen, and lastly the diaphragm. Recovery occurs in reverse order.
• Onset & Duration: IV administration acts within 1 minute, peaks at 3 to 5 minutes, and lasts 25 to 40 minutes.
• Metabolism & Elimination: 60% to 80% protein-bound. Active 3-desacetyl metabolite has 50% to 70% potency of parent compound. Elimination half-life: 65 mins (infants), 41 mins (children), and 65 to 75 mins (adults).

3. Core Clinical Dosing

• Rapid-Sequence Intubation (RSI):
  • Adults: 0.1-0.2 mg/kg IV (onset 2-4 mins).
  • Pediatrics (7 weeks to 17 years): 0.15-0.2 mg/kg IV (onset 2.5-3 mins).
  • Neonates (<7 weeks): 0.1 mg/kg IV (onset 2.5-3 mins).
• Mechanical Ventilation & Surgery:
  • Adults: 0.08-0.1 mg/kg initial IV bolus, then 0.01-0.015 mg/kg every 12-15 mins as needed, or continuous infusion of 0.8-1.7 mcg/kg/min.
• Defasciculation: 0.01 mg/kg IV given 1-3 mins before succinylcholine in adults. Rare in pediatrics.

4. Reconstitution & Stability

• Reconstitution: Add 10 or 20 mL of Bacteriostatic Water to 10 or 20 mg vials (1 mg/mL). For neonates, use Sterile Water to avoid benzyl alcohol toxicity.
• Storage: Bacteriostatic water reconstitution lasts 5 days (room temp/refrigerated); Sterile Water is single-use and discarded within 24 hours. Do not mix with alkaline solutions.

5. Monitoring & Adverse Effects

• Monitoring: Use a peripheral nerve stimulator to monitor response (target: 1 to 2 twitches).
• Adverse Reactions: Major risks include bronchospasm, anaphylaxis, acute myopathy, prolonged paralysis, tachycardia, and hypotension. Minimal histamine release occurs.

📊 I can generate a quick reference dosing card or a cheat sheet comparing these pediatric vs. adult infusion rates for your clinical review.

pick your specialty that you want to get into, learn the certs you need for them and go for it.